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Abstract: The review will discuss in detail the effects of polyphenols on breast cancer, including
both the advantages and disadvantages of the applications of these natural compounds. First, we
focus on the characterization of the main classes of polyphenols and then on in vitro and in vivo
experiments carried out in breast cancer models. Since the therapeutic effects of the administration of
a single type of polyphenol might be limited because of the reduced bioavailability of these drugs,
investigations on combination of several polyphenols or polyphenols with conventional therapy will
also be discussed. In addition, we present recent data focusing on clinical trials with polyphenols and
new approaches with nanoparticles in breast cancer. Besides the clinical and translational findings
this review systematically summarizes our current knowledge about the molecular mechanisms
of anti-cancer effects of polyphenols, which are related to apoptosis, cell cycle regulation, plasma
membrane receptors, signaling pathways and epigenetic mechanisms. At the same time the effects
of polyphenols on primary tumor, metastasis and angiogenesis in breast cancer are discussed. The
increasing enthusiasm regarding the combination of polyphenols and conventional therapy in breast
cancer might lead to additional efforts to motivate further research in this field.
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1. Introduction
Carcinogenesis is a complex and multistage process which, for easier comprehension, might be
classified to the following three main steps: initiation, promotion and progression [1,2]. Tumor initiation
was considered a rapid and irreversible process correlated with the exposure to the carcinogenic agent,
distribution of the carcinogenic agent to the cells, the interaction of the carcinogen or its metabolites
with DNA, leading in the end, to the appearance of the genotoxic effects. The second step, cancer
promotion, has been associated with proliferationof pre-neoplastic cells and it is considered a prolonged
and possibly reversible stage. The third step, tumor progression or neoplastic transformation is a process
accompanied by tumor growth, invasiveness and metastasis [1,2]. In accordance with the above
mentioned stages of carcinogenesis, a chemopreventive agent will be able to inhibit, delay or reverse
tumorigenesis or pre-malignant lesions [3,4]. De Flora and collaborators divided cancer chemopreventive
agents to three classes: primary, secondary and tertiary. Primary prevention blocks the occurrence of
the disease in healthy individuals by inhibiting mutagenesis and cancer initiation as well as tumor
promotion. Secondary prevention acts during preclinical or early stages of tumorigenesis by the inhibition
of tumor progression (i.e., antioxidant activity, modulation of signal transduction, modulation of
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hormones and immune status, inhibition of angiogenesis). Tertiary prevention is achieved by the
inhibition of invasion and metastasis in cancer patients after therapy and it includes the modulation of
cell-adhesion molecules, the inhibition of proteases involved in extracellular matrix degradation and
the activation of anti-metastatic genes [5,6]. Therapeutic effects in allopathic, mainstream medicine are
often achieved by acting on a single target. To the contrary, the effects of dietary agents must be seen as
a set of several effects rather than a single biological response and for this reason they might act on the
entire process of malignant transformation [7]. Since several authors have hypothesized that “multiple
weak hits confuse the complex system” [8,9], the pleiotropic effect of the polyphenols had been
considered appropriate to delay and to fight the carcinogenic processes in the breast tissue [10,11].
2. Breast Cancer—General Aspects
Despite the progress in the fight against malignancy, breast cancer incidence has still increased
worldwide, with more than 1.3 million cases associated with 450,000 deaths per year [12]. Apocrine
glands located in the skin were identified as the evolutionary origins of the mammary glands and
their main function is to provide nutrients to the newborn [13,14]. Since factors involved in the
development of the mammary gland are very similar to those required for a malignant process, a better
understanding of the normal physiology of breast development might help in deciphering the biology
of tumorigenesis [15]. Organogenesis of the mammary gland starts in the embryonic life followed by
a period of inhibition till puberty, when the mammary ducts are elongated and branched due to the
presence of invading structures called terminal end buds (TEB); the most intense morphological and
physiological changes take place during the adult life, due to pregnancy, lactation and after lactation
period when 80%–90% of the epithelial cells might be eliminated through an apoptotic process in a
few days [13,15,16].
In breast cancer several clinical features, such as age, tumor size, axillary lymph node status,
hormone and human epidermal growth factor receptor 2 (HER2) receptor status, histological grade or
the presence of metastasis are routinely investigated in order to provide the patients with the best
treatment [17]. A major challenge in the treatment of breast cancer is its high heterogeneity from
patient to patient which initiated its classification into three major molecular subtypes, according to
estrogen receptors (ER), progesterone receptors (PR) and HER2: hormone receptor positive with
luminal A (ER+PR+HER2´) and luminal B (ER+PR+HER2+) phenotypes, HER2 positive (ER´PR´HER2+)
and triple negative/basal-like (ER´PR´HER2´) [17–19]. The biomarker profile may be more complex
by including additional molecules to the previous classification: nuclear protein necessary
for cell proliferation (Ki67), cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor
(EGFR) [17,18]. About 70% of breast cancers are estrogen receptor positive [20]. In addition to the
application of conventional therapy, the non-specific chemotherapy of breast cancer is supplemented
with targeted drugs according to the molecular subtypes of the disease, namely: (i) the use of estrogen
antagonists, like tamoxifen, fulvestran or aromatase inhibitors in estrogen positive tumors and (ii)
the administration of anti-HER2 antibodies, like trastuzumab and tyrosine kinase inhibitors (TKI),
like lapatinib in HER2 positive tumors. Unfortunately, the application of systemic, conventional
chemotherapy: anthracycline family (doxorubicine) and taxane family (paclitaxel) remains the only
option in the treatment of triple negative breast cancer (TNBC) [21,22]. In addition to the therapy
targeted at the cancer cells themselves an antibody against vascular endothelial growth factor receptor
(VEGFR), bevacizumab, which inhibits angiogenesis, may also be administrated in combination with
the above mentioned drugs [21]. However, 25%–45% of patients develop metastatic disease [22,23].
Besides the beneficial effects of anti-cancer drugs, their side effects are significant; for instance,
administration of doxorubicine or taxol induces cardiotoxicity [24–26] and combination of anti-cancer
drugs can result in massive adverse effects [27]. Similarly, longtime administration of anti-cancer
drugs leads to drug resistance and further the development of recurrences [27]. The use of natural
compounds from edible fruits or vegetables presents an alternative way since they are pleiotropic
molecules with fewer side effects than conventional therapy [27].
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3. Polyphenols—General Aspects
Plants produce primary and secondary metabolites with the first category involved in essential
functions such as: photosynthesis, respiration and development, while the second one being
responsible for attracting pollinators, protecting against ultraviolet radiation and for defense
against herbivores and pathogens. Additionally, secondary metabolites provide humankind with
different drugs, antibiotics and herbicides [28,29]. The prolonged intake of secondary plant
metabolites has demonstrated favorable impact on cancer, cardiovascular diseases, type II diabetes
or neurodegenerative diseases [29–32]. Polyphenols are secondary plant metabolites found in fruits,
vegetables, spices, nuts, grains, tea, coffee or wine and they are recognized for their powerful
antioxidant properties [28,30]. Nevertheless, the pro-oxidant effect of polyphenols was also observed,
since after donating an electron or a hydrogen atom, they become reactive species capable of interacting
with other molecules [33–35]. Polyphenols are chemical compounds with more than one hydroxyl
functional group (–OH) attached to an aromatic ring [36]. More than 8000 species of polyphenols have
been identified in the plant kingdom and they are regularly present as glycosylated forms with one or
more sugar residues conjugated to a hydroxyl group or the aromatic ring [37,38].
Polyphenols are classified based on several criteria in line with their source, biological function or
chemical structure. According to the most recent classification polyphenols can be divided into two
major groups: (1) flavonoids; and (2) non-flavonoids [28,39]. Flavonoids include different subclasses
and the most representative ones are flavonols, flavones, flavan-3-ols, anthocyanidins, flavanones and
isoflavones [38]. Non-flavonoids comprise the following main classes: phenolic acids (benzoic acids
and cinnamic acids), stilbenes, lignans, tannins and other polyphenols (including curcumin, rosmarinic
acid, gingerol, etc.) [28,31,36]. Out of all polyphenol classes, 60% are represented by flavonoids and
30% by phenolic acids [31,40].
Flavonoids are the most representative group of polyphenols. They consist of 15 carbon atoms
(C6–C3–C6) characterized by two benzene rings joined by a three carbon chain forming an oxygenated
heterocycle [28,29,38]. The main dietary sources of flavonoids are fruits, vegetables, medicinal herbs,
spices, tea, coffee and wine. The daily intake of flavonoids is variable according to each subclass, namely:
0.1–1.2 mg (isoflavones), 0.3–1.6 mg (flavones), 5.4–27.4 mg (flavonols), 20.4–50.6 mg (flavanones),
12–189.2 mg (flavan-3-ols) and 180–215 mg (anthocyanins) [28]. The most well-known flavonoid
sub-classes are presented in Table 1 including members, chemical structure and dietary sources.
Non-flavonoids. The main non-flavonoid phenolic classes (Table 2) are represented by: phenolic
acids (hydroxybenzoates and hydroxycinnamates); polyphenolic stilbenes; polyphenolic tannis with
gallic acid as precursor of hydrolysable tannins (gallotannins, ellagitannis); other polyphenols:
curcumin, rosmarinic acid, gingerol etc. [39].
4. In Vitro Effect of Polyphenols
4.1. Antioxidant Activity of Polyphenols
Due to their ability to display both anti-oxidant and pro-oxidant activity polyphenols have been
considered “double-edge swords” [41]. The antioxidant activities of polyphenols have been broadly
studied, but they still need to be better understood. The main mechanisms of the antioxidant activity
of polyphenols can be summarized as follows: (i) free radical scavenger; (ii) metal chelating abilities;
(iii) inhibition of several types of oxidases (lypooxygenase, cyclooxygenase etc.); and (iv) stimulation of
enzymes with anti-oxidant properties (superoxide dismutase, catalase etc.) [42]. The free radical scavenger
activity of polyphenols was strongly correlated with their chemical structure, namely the presence of: (i)
catechol (1,2-dihydroxibenzen) group on the B-ring; (ii) 2,3-double bond conjugated with the 4-oxo-function
(oxygen atom double bonded to carbon) of the carbonyl group in the C-ring; and (iii) hydroxyl groups
at positions 3 and 5 [41]. On the other hand, the main pro-oxidant mechanisms of polyphenols have
been associated with: (i) generation of reactive oxygen species which in turn will induce mitochondrial
dysfunction in connection with apoptotic cell death [43]; and (ii) oxidative DNA damage [44].
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Table 1. Main classes of flavonoids with chemical structure, representative members and dietary sources [36,39,45,46].
Class of Flavonoid Chemical Structure Representative Members Dietary Sources
Flavonoids C6–C3–C6
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Table 1. Main classes of flavonoids with chemical structure, representative members and dietary sources [36,39,45,46]. 
Class of Flavonoid Che ical tr Representative Members Dietary Sources
Flavonoids  
C6–C3–C6 
Flavonols 
Quercetin  
Kaempferol  
Myricetin 
Onions (Allium cepa), spinach (Spinacia oleracea), cauliflower (Brassica oleracea Botrytis Group), strawberries 
(Fragaria ananassa) 
Flavones 
Apigenin  
Luteolin 
Celery (Apium graveolens), parsley (Petroselinum crispum), artichoke (Cynara scolymus) 
Flavan-3-ols/ 
proto-
anthocyanidins 
Epicatechin  
Epigallocatechin  
Epigallocatechin-3-O-
gallate (EGCG)  
Procyanidin 2 
Apricots (Prunus armeniaca), sour cherries (Prunus cerasus), grapes (Vitis ssp.), blackberries (Rubus ssp.), 
apples (Malus domestica) dark chocolate—seeds of cocoa (Theobroma cacao), mint (Mentha rodundifolia), basil 
(Ocimum basilicum), rosemary (Rosemarinus officinalis), sage (Salvia officinalis), dill (Anetheum graveolens), 
green tea (Camellia sinensis), hazelnuts (Corylus avellana), pecans (Carya illinoensis), almonds (Prunus dulcis), 
pistachios (Pistachio vera), walnuts (Juglans ssp.) 
Anthocyanidins/ 
Anthocynins 
Cyanidin  
Pelargonidin  
Delphinidin  
Malvidin 
Red grapes (Vitis labrusca, Vitis vinifera), cranberry (Vaccinium macrocarpon), blackberry (Rubus ssp.), 
elderberry (Sambucus nigra), blueberry (Vacciunium corymbosum), blackcurrant (Ribes nigrum), sweet cherries 
(Prunus avium), sour cherries (Prunus cerasus), plums (Prunus domestica), peaches (Prunus persica) 
Flavanones 
Naringerin  
Hesperitin 
Orange (Citrus sinensis), lemon (Citrus lemon), mandarin (Citrus reticulate), grapefruit (Citrus paradisi), 
tomatoes (Solamun lycopersicum) 
Isoflavones 
Genistein  
Daidzein  
Glycitin 
Soybean (Glycine max), beans (Phaseolus vulgaris), green peas (Pisum sativum) 
A C
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Epicatechin
Epigallocatechin
Epigallocatechin-3-O-gallate
(EGCG)
Procyanidin 2
Apricots (Prunus a meniaca), sour cherries (Prunus cerasus), grapes (Vitis ssp.),
blackb rries (Rubus ssp.), apples (Malus domestic ) dark chocolate—seeds of cocoa
(Theobroma cacao), mint (Mentha rodundifolia), basil (Ocimum basilicum), rosemary
(Rosemarinus officinalis), sage (Salvia officinalis), dill (Anetheum graveolens), green tea
(Camellia sinensis), hazelnuts (Corylus avellana), pecans (Carya illinoensis), almonds
(Prunus dulcis), pistachios (Pistachio vera), walnuts (Juglans ssp.)
Anthocyanidins/Anthocynins
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apples (Malus domestica) d rk chocolate—seeds of coco  (Theobroma cacao), mint (Mentha rodundifolia), basil 
(Ocimum basilicum), rosemary (Rosemarinus officinalis), sage (Salvia officinalis), dill (Anetheum graveolens), 
green tea (Camellia sinensis), hazelnuts (Corylus avellana), pecans (Carya illinoensis), almonds (Prunus dulcis), 
pistachios (Pistachio vera), walnuts (Juglans ssp.) 
Anthocya idins/ 
Anthocynins 
Cyanidin  
Pelargonidin  
Delphinidin  
Malvidin 
Red grapes (Vitis la rusca, Vitis vinifera), cranberry (Vacci  macrocarpon), bl kberry (Rubus ssp.), 
elderberry (Sambucus nigra), blueberry (Vacciunium corymbosum), blackcurrant (Ribes nigrum), weet cherri s 
(Prunus avium), sour cherries (Prunus cerasus), plums (Prunus domestica), peaches (Prunus persica) 
Flavanones 
Naringerin  
Hesperitin 
Orange (Citrus sinensis), lemon (Citrus lemon), mandarin (Citrus reticulate), grapefruit (Citrus paradisi), 
tomatoes (Solamun lycopersicum) 
Isoflavones 
Genistein  
Daidzein  
Glycitin 
Soybean (Glycine max), beans (Phaseolus vulgaris), green peas (Pisum sativum) 
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Table 2. The main classes of non-flavonoid polyphenols with chemical structure, representative members and dietary sources [36,39,45].
Class of Non-Flavonoids Chemical Structure Representative Members Dietary Sources
Phenolic acids—Benzoic
acids/hydroxybenzoates
C6–C1
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Administration of EGCG in reduced doses (10, 20 µM) was associated with decreased levels of
reactive oxygen species (ROS) in MCF-10A transformed with a combination of carcinogens [47] and in
Hs578T breast cancer cells, while higher doses (100 µM) increased the production of ROS in Hs578T
breast cancer cells [48]. On the other hand, 10 µM EGCG failed to modulate the level of superoxide
dismutase or catalase, but increased the expression of quinone reductase 1 in MCF-7 breast cancer cells.
At the same time, resveratrol displayed similar effects to EGCG on superoxide dismutase, catalase and
quinone reductase 1 in MCF-7 cell line, but its dose dependence was opposite to that of EGCG [49].
Incubation of MCF-7 cells with 10 µM resveratrol induced an increase in ROS production, while 100 µM
resveratrol decreased it [50]. Administration of low doses of quercetin (0.62 µM for 24 h) did not change
the levels of ROS in MCF-7 and MDA-MB-231 breast cancer cells [51], but higher doses of quercetin
increased the level of ROS in MDA-MB-468 breast cancer cell line [52]. Physiological doses of genistein
(1 µM) administrated for 48 h increased copper and zinc superoxide dismutase (CuZn-SOD) and
manganese superoxide dismutase (Mn-SOD) in the T47D cell line, but not in MCF-7 cells and it did not
significantly influence catalase levels suggesting that the anti-oxidant effect of genistein was cell line
dependent which may be correlated with the ERα/ERβ ratio [53]. The apoptotic activity of genistein
in breast cancer cells was correlated with a ROS production. Thus, administration of 50 µM genistein
led to apoptosis, while ROS scavengers induced the opposite effects in MDA-MB-231, MDA-MB-468,
but not in MCF-10A cells [54]. Treatment with 10–100 µM curcumin induced time-dependent increase
in ROS production in MCF-7 and MDA-MB-231 breast cancer cell lines, demonstrating a pro-oxidant
effect [50]. On the contrary, curcumin prevented the increased production of ROS induced by nickel
oxide nanoparticles in MCF-7 cells [55]. The contradiction regarding the pro- or antioxidant effects of
polyphenols may be the result of differences in the cell models or experimental conditions. However,
some of the polyphenols (EGCG) displayed double effects as hypothesized, both anti- and pro-oxidant,
and these effects were correlated with dose-dependent administration. Additional data in breast cancer
cell lines and animal models are required to clarify and confirm the previous results.
4.2. Polyphenols and Aromatase Inhibitor Activity
The cytochrome P450 enzyme complex or aromatase is able to convert androgens (C19) to estrogens
(C18) [56,57]. Under normal conditions, estrogens are responsible for reproduction, neuroendocrine
activity and for the development of female reproductive organs [58,59]. While aromatase is
physiologically expressed in the ovaries of premenopausal women, in the placenta of pregnant women,
in the adipose tissue of postmenopausal women and in breast tissue, it is pathologically produced
by cancer-associated fibroblasts in breast cancer. Several factors are responsible for the activation of
aromatase in breast tissue: prostaglandin-E2 (PGE2) released by breast cancer cells or inflammatory cells
and cytokines (IL-6, IL-11 and TNFα) produced by inflammatory cells [56]. Since 70% of breast cancers
are estrogen dependent, aromatase inhibitors are used for treating these tumors. Aromatase inhibitors
can be classified into two groups (Figure 1A): (i) steroidal aromatase inhibitors, whose structure is similar
to that of the natural substrate, adrostendione. They act as false substrates and are processed to
an intermediate binding irreversibility to the active site. The mechanism of action is referred to as
“suicide inhibition”. Formestane (2nd generation) and exemestane (3rd generation) are examples
of such inhibitors; (ii) non-steroidal aromatase inhibitors, which are reversible, competitive inhibitors
since they bind to the iron atom in the heme group of aromatase with their nitrogen atom
present in imidazole, triazole, pyrimidine or pyridine groups. Examples of non-steroidal inhibitors
include: aminoglutethimide (1st generation), fadrozole (2nd generation), triazoles (3rd generation). The
third generation inhibitors: anastrozole and letrozole are 100–3000 times more active than
aminoglutethimide [56,57]. Besides the main steroidal and non-steroidal aromatase inhibitors,
flavonoids and flavonoid derivatives attracted attention due to their ability to inhibit aromatase
activity [60,61]. Flavonoids and flavonoid derivatives contain two structural features which can
contribute to their aromatase inhibitory activity: (i) A and C rings of the flavonoids may mimic D and
C rings of the aromatase substrate (androstendione) and (ii) oxo-group in C4 position was considered
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essential to bind the iron atom of the heme group of aromatase [57]. At the same time, it has been
noticed that flavones and flavanones display higher inhibitory activity compared to isoflavones and
isoflavanones [62]. Nevertheless, a major drawback of flavonoids and flavonoid derivatives is their
pleiotropic effect. Their multiple interactions with many biological molecules set limitations for their
therapeutic applications [63].
A recent report concluded that luteolin, a dietary flavonoid, demonstrated aromatase inhibitor
activity at low concentrations (2.44 µM) [64]. However, another dietary flavonoid, hesperitin increased
the expression of aromatase at the mRNA level suggesting that dietary flavonoids could regulate
aromatase expression differentially [65]. The results of a high-throughput study screening of 7000
compounds identified an imidazolyl quinoline derivative of flavonoids with aromatase inhibitor effect
at a concentration of 0.81 µM decreasing the proliferation of T47D breast cancer cells [66]. Based
on the structure of isoflavanones a new class of aromatase inhibitors has been developed with the
ability to inhibit aromatase activity in the concentration range of 0.26 to 5.8 µM [67]. Polyphenols
from black tea have been shown to inhibit aromatase activity and to decrease the proliferation of
dehydroepiandrosterone-induced MCF-7 cells by one study only [68]. Satoh et al. also concluded that
several components of green tea extract, including EGCG have aromatase inhibitory activity with
IC50 values in the micromolar range [69]. A schematic mechanism of action in case of polyphenols as
inhibitors of aromatase is shown in Figure 1B.
Molecules 2015, 20, page–page 
7 
major drawback of flavonoids and flavonoid derivatives is their pleiotropic effect. Their multiple 
interactions with many biological molecules set limitations for their therapeutic applications [63]. 
A recent report concluded that luteolin, a dietary flavonoid, demonstrated aromatase inhibitor 
activity at low concentrations (2.44 µM) [64]. However, another dietary flavonoid, hesperitin increased 
the expression of aromatase at the mRNA level suggesting that dietary flavonoids could regulate 
aromatase expr ssion differentially [65]. The r sults of a high-thr ughput study screening of 7000 
compounds identified an imidazolyl quinoline deriv ive of flavonoids with aromatase inhibitor 
effect at a concentration of 0.81 µM decreasing the proliferation of T47D breast cancer cells [66]. Based 
on the structure of isoflavanones a new class of aromatase inhibitors has been developed with the 
ability to inhibit aromatase activity in the concentration range of 0.26 to 5.8 µM [67]. Polyphenols 
from black tea have been shown to inhibit aromatase activity and to decrease the proliferation of 
dehydroepiandrosterone-induced MCF-7 cells by one study only [68]. Satoh et al. also concluded that 
several components of green tea extract, including EGCG have aromatase inhibitory activity with 
 IC50 values in the micromolar range [69]. A schematic mechanism of action in case of polyphenols as 
inhibitors of aromatase is shown in Figure 1B.  
 
Figure 1. Poyphenols as aromatase inhibitory molecules. (A) Chemical structure of aromatase inhibitors 
and natural substrates. a. androstenedione (substrate for aromatase); b. exemestane (3rd generation 
steroidal inhibitor); c. letrozole (3rd generation non-steroidal inhibitor); d. luteolin (flavonoid) [56,57]; 
(B) Schematic mechanism of activity of aromatase inhibitors in relation to nuclear estrogen receptors. 
Androgens (androstendione and testosterone) are converted to estrogens (estrone and estradiol) by 
aromatase; estradiol enters the nucleus and binds to estrogen receptors (ER) which interacts with estrogen 
response elements (ERE) triggering cell proliferation. So far, luteolin, flavonoid and isoflavonoid 
derivatives have been found to inhibit aromatase activity in breast cancer cells [64,66,67]. 
Beside these promising results, genistein in an in vitro model based on co-culture between  
MCF-7 cells and primary breast adipose fibroblasts increased aromatase activity and canceled the 
aromatase inhibitor activity of fadrozole [70]. So far the efficacy of flavonoids and their derivatives 
has not been conclusively shown, due to the lack of data or contradictory results. Additional 
experiments including in vitro and in vivo assays as well as clinical trials are still required. 
  
Figure 1. Poyphenols as aromatase inhibitory molecules. (A) Chemical structure of aromatase inhibitors
and natural substrates. a. androstenedione (substrate for aromatase); b. exemestane (3rd generation
steroidal inhibitor); c. letrozole (3rd generation non-steroidal inhibitor); d. luteolin (flavonoid) [56,57];
(B) Schematic mechanism of activity of aromatase inhibitors in relation to nuclear estrogen receptors.
Androgens (androstendione and testosterone) are converted to estrogens (estrone and estradiol)
by aromatase; estradiol enters the nucleus and binds to estrogen receptors (ER) which interacts
with estrogen response elements (ERE) triggering cell proliferation. So far, luteolin, flavonoid and
isoflavonoid derivatives have been found to inhibit aromatase activity in breast cancer cells [64,66,67].
Beside these promising results, genistein in an in vitro model based on co-culture between MCF-7
cells and primary breast adipose fibroblasts increased aromatase activity and canceled the aromatase
inhibitor activity of fadrozole [70]. So far the efficacy of flavonoids and their derivatives has not been
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conclusively shown, due to the lack of data or contradictory results. Additional experiments including
in vitro and in vivo assays as well as clinical trials are still required.
4.3. Reversal of Glycolytic Metabolism by Polyphenols
Since 1924 it has been established that cancer cells display intense glycolysis even in the presence
of oxygen and the effect was coined, according to its discoverer, Warburg effect. This effect can be
observed nowadays during positron emission tomography with [18F]-fluoro-2-deoxyglucose (18F-FDG),
since cancer cells have a more rapid uptake of glucose compared to the normal ones [71]. In order
to obtain energy, cancer cells prefer aerobic glycolysis (i.e., glycolysis even in the presence of oxygen),
while normal cells favor mitochondrial oxidative phosphorylation. As a result cancer cells obtain only two
molecules ATP per molecule glucose while normal cells may acquire 32 molecules of ATP per molecule
glucose [72,73]. The obviously inefficient production of ATP raises the question: why cancer cells
prefer a low efficiency of ATP generation although they are highly proliferative systems? A possible
answer may be related to the fact that during aerobic glycolysis ATP is generated with low efficiency,
but at higher rate; on the contrary in the mitochondrial oxidative phosphorylation ATP is generated
with high efficiency, but at slower rate. In addition, cancer cells also exploit the glycolytic pathway
to obtain precursors for nucleotides, fatty acids and amino acids which are required for nucleic acid
generation, membrane biogenesis and protein synthesis in highly proliferating systems [74,75].
Figure 2 shows schematically the main pathways preferentially utilized by cancer cells: aerobic
glycolysis, fatty acid synthesis and glutaminolysis. Briefly, glucose after the cellular uptake is
phosphorylated to glucose-6-phosphate by hexokinases; glucose-6-phosphate during the pentose
phosphate pathway can be metabolized to ribose-5-phosphate in the presence of glucose-6-phosphate
dehydrogenase and further used for nucleotide synthesis. In a series of consecutive steps
glucose-6-phosphate is metabolized to phosphoenolpyruvate through the intermediate products
fructose-6-phosphate, fructose-1,6-biphosphate, glyceradehyde-3-phosphate and 3-phosphoglycerate.
In the presence of the M1 (adult) splice variant of pyruvate kinase phosphoenolpyruvate is transformed
to pyruvate and further on pyruvate in the presence of lactate dehydrogenase A is metabolized to
lactate which will be released by the cells through the monocarboxylate transporters [72,75,76]. On the
other hand, tumor cells express the M2 (embryonic) splice variant of pyruvate kinase which performs
the conversion of phophoenolpyruvate to pyruvate much more slowly resulting in the accumulation
of all glycolytic intermediates before pyruvate [77]. Inhibition of the expression of the M2 isoform of
pyruvate kinase not only resulted in reversal of the Warburg effect, but also led to a reduced ability to
form tumors in nude mice [78].
Intermediary molecules of this pathway can be further utilized in anabolic processes, e.g.,
glyceraldehyde-3-phosphate for lipid synthesis, 3-phosphoglycerare for amino acid synthesis and
pyruvate for fatty acid synthesis via the tricarboxylic cycle. In glutaminolysis glutamine is converted to
glutamate by glutaminase and then to α-ketoglutarate. Cancer cells prefer glutamine as the main source
of carbon in the tricarboxylic cycle [75]. Since cancer cells are dependent on aerobic glycolysis [78],
the enzymes contributing to glucose metabolism may represent an attractive target for cancer therapy.
Nevertheless an open question remains here: is it appropriate to target molecules expressed both in
normal and in cancer cells non-selectively? So far, only a few studies have described the ability of
polyphenols to inhibit the glycolytic pathway in breast cancer cells. 150 µM resveratrol administrated
for 24 h decreased 18F-FDG uptake by 35% in T47D mammary cancer cells, but the mechanism of
action remains to be clarified [79]. The enzyme 6-phosphofructo-1-kinase (PFK) may be considered
one of the main enzymes in the glycolytic pathways, since its levels have been linked to glucose intake.
The administration of resveratrol (1–100 µM for 24 h) to MCF-7 breast cancer cells was associated
with decreased glucose uptake, increased lactate production, decreased intracellular ATP content and
inhibition of PFK activity. Since cancer cells express all isoforms of PFK the mechanism of action of
resveratrol must be characterized in terms of its effect on different isoforms.
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The rate of aerobic glycolysis in cancer cells is increased in detriment of ATP production. The 
intermediate compounds from the glycolytic pathway are further used to synthetize nucleotides, amino 
acids and lipids required for the proliferation of cancer cells [72,75,76,80]. The glucose transporter can 
be inhibited by EGCG, quercetin, phloretin, kaempferol [81–83], PFK by resveratrol [84], and MCT by 
kaempferol [83]. Abbreviations: PEP, phosphoenolyruvate; TCA, tricarboxylic acid cycle; F-2,6-BP, 
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Administration of resveratrol induced the dissociation of the tetrameric PFK-M isoform, isolated 
from rabbit skeletal muscle to a less active form, the dimer [84]. Glucose uptake was investigated in 
MCF-7 and MDA-MB-231 breast cancer cells using 3H-2-deoxy-D-glucose (3H-DG). The consumption 
of 3H-DG in breast cancer cells was found to be suppressed by cytochalasin B, a glucose transporter 
inhibitor, moderately stimulated by insulin and independent of sodium suggesting that it was mainly 
mediated by the GLUT family of transporters rather than by sodium-glucose transporter. Administration 
of EGCG and quercetin suppressed 3H-DG uptake in a concentration-dependent manner in both cells 
lines and inhibited lactate production only in MCF-7 cells, suggesting that EGCG and quercetin might 
be considered possible therapeutic/adjuvant agents in breast tumors [81]. Recent data demonstrated 
that two flavonoids, quercetin and phloretin (0.6–300 µM) inhibited glycolysis indicated by increased 
glucose and decreased lactate concentrations in the cell culture media of MCF-7 and HBL100 breast 
cancer cells after 24 h of exposure [82]. The effect of several polyphenols (myricetin, chrysin, genistein, 
resveratrol and kaempferol with concentration range 10–100 µM) was investigated in a short-term 
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(MCT). The rate of aerobic glycolysis in cancer cells is increased in detriment of ATP production. The
intermediate compounds from the glycolytic pathway are further used to synthetize nucleotides, amino
acids and lipids required for the proliferation of cancer cells [72,75,76,80]. The glucose transporter can
be inhibited by EGCG, quercetin, phloretin, kaempferol [81–83], PFK by resveratrol [84], and MCT
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Administration of resveratrol induce he dissociation of the tetrameric PFK-M isoform, isolated
from rabbit skeletal muscle to a less active form, the dimer [84]. Glucose uptake was investigated in
MCF-7 and MDA-MB-231 breast cancer cells using 3H-2-deoxy-D-glucose (3H-DG). The consumption
of 3H-DG in breast cancer cells was found to be suppressed by cytochalasin B, a glucose transporter
inhibitor, moderately stimulated by insulin and independent of sodium suggesting that it was
mainly mediated by the GLUT family of transporters rather than by sodium-glucose transporter.
Administration of EGCG and quercetin suppressed 3H-DG uptake in a concentration-dependent
manner in both cells lines and inhibited lactate production only in MCF-7 cells, suggesting that EGCG
and querce in might be considered p ssible herapeutic/adjuvant agents in breast tumors [81]. Recent
data demonstrated that two flavonoids, quercetin and phloretin (0.6–300 µM) inhibited glycolysis
indicated by increased glucose and decreased lactate concentrations in the cell culture media of MCF-7
and HBL100 breast cancer cells after 24 h of exposure [82]. The effect of several polyphenols (myricetin,
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chrysin, genistein, resveratrol and kaempferol with concentration range 10–100 µM) was investigated
in a short-term experiment (26 min), resulting in the selection of kaempferol as the most potent inhibitor
of 3H-DG uptake in MCF-7 cells (IC50 4 µM). In the long-term experiment (24 h) 30 µM kaempferol
inhibited 3H-DG uptake and decreased GLUT1 mRNA levels by 40% associated with inhibition of
monocarboxylated transporter (MCT-1) [83]. Taken together the above mentioned reports suggest
that polyphenols may be considered as natural inhibitors of the glycolytic pathway in cancer cells
(Figure 2).
4.4. Regulation of Cell Cycle and Apoptosis by Polyphenols
The cell cycle (Figure 3) is a regulated sequence of events in which the mother cell divides
generating two daughter cells. During all these events pro- and anti-proliferative factors compete
with each other determining whether a cell divides, stops in the cell cycle or dies. Factors favoring
proliferation may be of intracellular (e.g., complexes between cyclins and cyclin dependent kinases
(Cdk), regulatory proteins, checkpoints etc.) or extracellular origin (e.g., growth factors and cell
adhesion molecules) [85,86]. Beside stimulatory molecules (cyclin-Cdk complexes and eukaryote
transcription factor, E2F), the cell cycle is regulated by Cdk inhibitory proteins (retinoblastoma tumor
suppressor protein (Rb), p15, p16, p21, p27 and p53) [87,88]. In tumor cells the cyclin-Cdk complexes
are overexpressed, while the inhibitory proteins display a low expression [89]. Although cells attempt
to correct mutations in DNA, extensive damage revealed at cell cycle check points may lead to
programmed cell death, i.e., apoptosis [90,91]. Apoptosis (Figure 4) is initiated by two interconnected
signaling routes: (i) extrinsic pathway which operates through the cell surface death receptors; and
(ii) intrinsic pathway which involves the disruption of mitochondrial membrane integrity, both of
them having as common effectors a family of cysteine aspartic proteases (caspases) [92,93]. The
extrinsic pathway involves the engagement of death receptors. Two main types of death receptor
complexes are presented in Figure 4: (i) first group, death-inducing signaling complexes (DISC)
includes cluster of differentiation (CD) molecules, like CD95 or tumor necrosis factor receptor
superfamily member 6 (Fas) with its ligand (CD95L/FasL), Fas-associated death domain protein
(FADD) and pro-caspase-8,10; (ii) the second group, represented by tumor necrosis factor receptor 1
(TNFR1), which after the binding of tumor necrosis factor (TNF) will recruit receptor interacting protein
(RIP), TNFR1-associated death domain protein (TRADD) and TNFR-associated factor (TRAF) [94,95].
Death receptors, through activated caspase-8,10, will further trigger the executioner caspases-3,6,7
which will lead to the formation of apoptotic bodies [96,97]. However, TNFR1 in connection with
the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway can prevent
TNF induced apoptosis [98]. The intrinsic pathway acts through B-cell lymphoma 2 protein (Bcl-2)
family of proteins and can be triggered by diverse stress factors which will activate Bcl-2 homology
domain 3-interacting domain death agonist (Bid), which, in turn, activates Bcl-2 associated X protein
(Bax)/Bcl-2 homologus killer (Bak) oligomeric complexes localized in the mitochondrial membrane.
These complexes are also responsible for the efflux of cytochrome c from mitochondria. Cytochrome c
together with apoptotic protease activator factor 1 (APAF-1) will form the apoptosomes, which will
activate caspase-9 connected further with executioner caspases-3,6,7. Apoptotic signals can be inhibited
by anti-apoptotic proteins: Bcl-2 and B-cell lymphoma-extra-large protein (Bcl-XL). Sometimes there
is cross-talk between the extrinsic and intrinsic pathways, through caspase-8 and Bid. Activation of
the survival pathway by phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) can inhibit the
pro-apoptotic protein, Bcl-2-associated death promoter (Bad) [95].
In the MCF-7 breast cancer cell line the cell cycle progression may be stimulated by the cooperation
between 17β-estradiol (E2) and insulin-like growth factor-I (IGF-I). Thus, E2 and IGF-1 can stimulate
the expression of cyclin D1, Cdk2, Cdk4 [99]. Polyphenols were shown to inhibit proliferation and
cell cycle progression. Administration of 5 and 10 µM quercetin-3-methyl ether to wild-type and
lapatinib-resistant SK-BR-3 breast cancer cells for 16 and 48 h induced significant accumulation of
cells in the G2/M phase, which was correlated with increased levels of cyclin B1/p-cyclin B1 (Ser 147),
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cell division cycle 225 proteins (Cdc225): Cdc225/p-Cdc225 (Ser216) and check point kinase (Chk)
Chk1/p-Chk1 (Ser345) in sensitive SK-BR-3 cells, but not in resistant ones [100]. In MDA-MD-453
breast cancer cell line 100 µM quercetin applied for 24 h induced an increase in the fraction of cells
in the G2/M phase associated with a decrease in the fraction of cells residing in the G1 phase [101].
Administration of 25 and 50 µM resveratrol for 3 days induced the increase of the percentage of MCF-7
cells in the G2/M phase, while similar concentrations lead to an accumulation of cells in the S phase in
correlation with a reduction in the fraction of cells in the G1 phase in MDA-MB-231 breast cancer cells,
suggesting cell line dependent effects [102].
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cyclin-Cdk complexes and eukaryote transcription factor (E2F) in blue and (ii) inhibitory proteins: 
retinoblastoma protein (Rb), p15, p16, p21, p27 and p53 in red; phosphorylation of Rb will release E2F 
which further stimulates cell cycle progression; p53, the tumor suppressor protein is responsible for 
stimulation of p21 and p27 expression, two inhibitory proteins of the cyclin-Cdk complexes [103–108]. 
Quercetin, resveratrol, curcumin, genisteins and apigenin arrest the cells in G2/M phase, while 
resveratrol and genistein in S phase; apigenin inhibits Cyclin A, B-Cdk1 complexes, and stimulate p21 
and p27; curcumin, apigenin and resveratrol increase the activity of p53 [100–102,109–113]. Blue and 
red lines indicate stimulation and inhibition, respectively, of the process (for the sake of simplicity 
only the major proteins involved in cell cycle regulation are shown). 
Curcumin induced a series of effects related to the inhibition of the mitotic spindle in MCF-7 breast 
cancer cell line including depolymerization of mitotic microtubules, modification of microtubule 
kinetochore attachment, disturbed mitotic spindle structure and perturbed the localization of a member 
of the kinesin-5 subclass of kinesins (Eg5). Moreover, curcumin induced monopolar spindle formation 
associated with the accumulation of mitotic arrest deficient 2 proteins (Mad2) which in turn activated 
the mitotic checkpoints. Also, administration of 35 µM curcumin for 4 and 8 h induced mitotic arrest of 
MCF-7 cells [109]. Due to increased structural similarity between E2 and genistein, the polyphenol 
greatly influenced the cell cycle progression. In a more complex experiment Tominaga and coworkers 
also investigated the effect of genistein on the cell cycle. The experiments were started with four mouse 
cell lines derived from mammary tumors and the administration of 20–80 µM genistein inhibited the 
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Curcumin induced a series of effects related to the inhibition of the mitotic spindle in MCF-7
breast cancer cell line including depolymerization of mitotic microtubules, modification of microtubule
kinetochore atta hment, di turbed itotic spindle stru ture and perturbed the localization of a member
of the kinesin-5 subclass of kinesins (Eg5). Moreover, curcumin induce monopolar spindl f rmation
associated with the accumulation of mitotic arrest deficient 2 proteins (Mad2) which in turn activated
the mitotic checkpoints. Also, administration of 35 µM curcumin for 4 and 8 h induced mitotic arrest
of MCF-7 cells [109]. Due to increased structural similarity between E2 and genistein, the polyphenol
greatly influenced the cell cycle progression. In a more complex experiment Tominaga and coworkers
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also investigated the effect of genistein on the cell cycle. The experiments were started with four mouse
cell lines derived from mammary tumors and the administration of 20–80 µM genistein inhibited
the growth of all the mammary cancer cells investigated after 3 days of exposure, while long-term
exposure (7 days) to 15 µM genistein significantly decreased the survival of the W780 cell line only. In
accordance with previous data, administration of genistein for 3 days increased the number of cells in
the S/G2 phase accompanied by a reduction in the fraction of cells in G1. Besides the blocking in cell
cycle progression, DNA damage was also increased suggested by the increased level of histone 2A
variant phosphorylated at serine 139 (γ-H2AX). This phenomenon may have led to the appearance
of cells in the sub-G1 peak. The increased polyploidy (4n and 8n), observed also after genistein
treatment, may have been related to abnormal chromosomal structures in anaphase and the inhibition
of topoisomerase II, an enzyme responsible for the segregation of chromosomes [110]. The effect
of genistein was recently investigated on human breast cancer cell lines, MCF-7 (high ERα/ERβ
ratio), T47D (low ERα/ERβ ratio) and MDA-MB-231 (ER-negative) indicating that the treatment
with genistein at physiological concentrations (1 µM) for 48 h increased the fraction of cells in the
S/G2/M phases at the expense of the G1 phase in MCF-7 cells with no effects observed in T47D and
MDA-MB-231 cells suggesting that a high ERα/ERβ ratio may be a marker for an augmented response
to genistein [111]. However, in spite of pleiotropic effects of genistein in different breast cancer cell
lines, there seems to be an agreement that genistein leads to blockage of the cells in the S and G2/M
phases [114].
Molecules 2015, 20, page–page 
12 
growth of all the mammary cancer cells investigated after 3 days of exposure, while long-term exposure 
(7 days) to 15 µM genistein significantly decreased the survival of the W780 cell line only. In accordance 
with previous data, administration of genistein for 3 days increased the number of cells in the S/G2 
phase accompanied by a reduction in the fraction of cells in G1. Besides the blocking in cell cycle 
progression, DNA damage was also increased suggested by the increased level of histone 2A variant 
phosphorylated at serine 139 (γ-H2AX). This phenomenon may have led to the appearance of cells 
in the sub-G1 peak. The increased polyploidy (4n and 8n), observed also after genistein treatment, may 
have been related to abnormal chromosomal structures in anaphas  and the inhibition of topoisomerase 
II, an enzyme responsible for the segregation of chromosomes [110]. The ffect of genistein was r cently 
investigated on human breast cancer cell lines, MCF-7 (high ERα/ERβ ratio), T47D (low ERα/ERβ 
ratio) and MDA-MB-231 (ER-negative) indicating that the treatment with genistein at physiological 
concentrations (1 µM) for 48 h increased the fraction of cells in the S/G2/M phases at the expense of the 
G1 phase in MCF-7 cells with no effects observed in T47D and MDA-MB-231 cells suggesting that a 
high ERα/ERβ ratio may be a marker for an augmented response to genistein [111]. However, in spite 
of pleiotropic effects of genistein in different breast cancer cell lines, there seems to be an agreement 
that genistein leads to blockage of the cells in the S and G2/M phases [114].  
 
Figure 4. The effect of polyphenols on apoptotic signaling pathways. Extrinsic (1) and intrinsic (2) 
apoptosis pathways are shown in the figure. The proteins with pro-apoptotic activity (caspases, Bax, 
Bak, Bid, Bad, IkB) are colored in blue, while the proteins with anti-apoptotic action (Bcl-2, Bcl-XL, PI3K, 
Akt, IKK, NF-kB) in red. EGCG, resveratrol, genistein and curcumin can inhibit anti-apoptotic proteins 
(Bcl-2) and stimulate the pro-apoptotic ones (Bax, Bak); caspases are stimulated by EGCG, quercetin and 
apigenin; the anti-apoptotic activity of NF-kB can be inhibited by apigenin [115–121]. Blue and red lines 
indicate stimulation and inhibition, respectively, of the process (for the sake of simplicity only the 
major proteins of the apoptosis pathways are shown). 
  
Figure 4. The effect of polyphenols on apoptotic signaling pathways. Extrinsic (1) and intrinsic (2)
apoptosis pathways are shown in the figure. The proteins with pro-apoptotic activity (caspases, Bax,
Bak, Bid, Bad, IkB) are colored in blue, while the proteins with anti-apoptotic action (Bcl-2, Bcl-XL,
PI3K, Akt, IKK, NF-kB) in red. EGCG, resveratrol, genistein and curcumin can inhibit anti-apoptotic
proteins (Bcl-2) and stimulate the pro-apoptotic ones (Bax, Bak); caspases are stimulated by EGCG,
quercetin and apigenin; the anti-apoptotic activity of NF-kB can be inhibited by apigenin [115–121].
Blue and red lines indicate stimulation and inhibition, respectively, of the process (for the sake of
simplicity only the major proteins of the apoptosis pathways are shown).
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Administration of 50 µM apigenin inhibited the proliferation of SK-BR-3 breast cancer cells
in correlation with a cell cycle arrest in the G2/M phase induced by increased expression of p21
and p27, and reduced expression of cyclin A, B, D and E and Cdk1 [112]. In conclusion, the major
anti-proliferative effect of several polyphenols (quercetin, resveratrol, genistein and apigenin) has been
shown to be associated with G2/M phase arrest.
It was reported in 1998 that 40 µM EGCG inhibited the growth of Hs758T breast cancer cells, but
this effect was not observed in their normal counterparts. The reduction in cell density was explained
based on the apoptotic effects, demonstrated by terminal deoxynucleotidyl transferase assay [122].
Apoptosis was also induced in MDA-MB-231 breast cancer cells by EGCG (50 and 80 µM) associated
with reduced Bcl-2 and Bax expression [115]. Physiological concentrations of EGCG (8 µM) applied
in long-term cultures of the same aggressive metastatic breast cancer cell line induced 1.5- to 2-fold
higher levels of the basal caspase-3/7 activity [116].
One of the clinical issues after antibody therapy is the development of resistance. Thus, EGCG
was investigated for its anti-cancer effects in JIMT-1, a cell line resistant to trastuzumab since its
isolation, and in trastuzumab resistant BT474 cells generated by continuous exposure to the antibody.
Exposure of the trastuzumab resistant breast cancer cell lines to 80 and 160 µg/mL EGCG for 72 h led
to decrease in cell growth and apoptosis at high concentrations associated with decreased Akt activity
and induction of Forkhead box O3 transcription factor protein (FOXO3) [123]. The overexpression
of 67-kDa laminin receptor (67LR) has been observed in several cancer tissues, including breast
cancer, and this phenotype was correlated with tumor progression [124,125]. 67LR was identified as
a receptor for EGCG [126] and a modulator of the apoptotic effects induced by the polyphenol [124].
Administration of 75 µM EGCG for 72 h induced late apoptosis/necrosis in SK-BR-3 breast cancer
cell line with HER2 overexpression, possibly through 67LR mediated pathway [127]. Not only the
EGCG but the other polyphenols can also induce apoptosis. In addition to a block the progression in
cell cycle 5 and 10 µM quercetin-3-methyl ether also induces apoptosis evidenced by increased levels
of cleaved caspase 3/7 and poly (adenosine diphosphate-ribose) polymerase (PARP) cleavage [100].
Apoptosis was also induced in MCF-7 breast cancer cells by 150 µM quercetin and it was associated
with decreased levels of Bcl-2, reduced mitochondrial membrane potential and enhanced level of
activated caspase-6, -8, -9 [117]. Induction of apoptosis by 30 and 50 µM resveratrol was dependent on
the expression of constitutively active signal transducer and activator of transcription 3 (STAT3) [128].
Experiments with resveratrol in MCF-7 breast cancer cells revealed that the polyphenol acts as an
estrogen receptor agonist, but, at the same time, reduces the Bcl-2/Bax ratio implying that it is
a candidate for hormone replacement therapy (HRT) [118]. Moreover, treatment with resveratrol
induced increased expression of p53, cleavage of PARP and this phenomenon was dependent on
nuclear factor erythroid 2 [NF-E2]-related factor 2 (NRF2), which is known as a molecule involved in
regulation of the antioxidant response [129].
Recent experiments tested the hypothesis that the inhibition of the IGF1R/Akt/Bcl-2/Bax
pathways is responsible for the apoptotic effects of genistein in MCF-7 breast cancer cells. The
presence of 40 and 80 µM genistein for 48 h in the cell culture medium induced apoptosis, increased
Bax messenger RNA (mRNA) and protein levels, decreased Bcl-2 mRNA and protein levels, decreased
insulin growth factor receptor (IGFR) and Akt protein levels [119]. Apigenin was also reported to
be involved in apoptosis of breast cancer cells. The inhibition of the proliferation of SK-BR-3 cells
by apigenin was correlated with the appearance of a subG0/G1 population, enhanced levels of
cleaved caspase-3/8 and PARP, supporting the hypothesis that apigenin induced apoptosis through
a caspase-dependent pathway [120]. Moreover, genetically modified MCF-7 cells overexpressing
HER2 exhibited apoptosis through the extrinsic pathway, by activation of p53 and inhibition of
STAT3 and NF-κB signaling pathways [116]. Recent data support the involvement of curcumin in
apoptosis induction as well. Curcumin increased the percentage of breast cancer cells with low level
of HER2 in the subG1 population and these data were confirmed by increased Bax/Bcl-2 ratio [121].
Administration of 30 µM curcumin for 48 h induced mainly early apoptosis associated with little late
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apoptosis in MDA-MB-231 (ER´/PR´/HER2´/EGFR+) breast cancer cells, a model of triple negative
breast cancer which is associated with poor prognosis. In MCF-7 breast cancer cells the administration
of 12, 24, 36 µM curcumin for 48 h induced early and late apoptosis confirmed by nuclear accumulation
of p53 and p21 [109]. To sum up, polyphenols under different environmental conditions may induce
processes associated with early or late apoptosis, decreased expression of anti-apoptotic proteins
and increased expression of the pro-apoptotic ones. However, most of the concentrations applied in
in vitro studies are high and this may represent a drawback for clinical applications. Additional studies
with physiological concentrations administrated for a longer time or animal experiments to check the
toxicity of polyphenols at higher concentrations will help us understand the utility of polyphenols
in practice.
4.5. Estrogen Receptors and Polyphenols
Estrogen hormones are thought to be key mediators for the development of the female
reproductive system and for the progression of breast cancer [130,131]. Since it was noticed
that estrogen administration was associated with breast cancer [132], it has been proposed
that phytoestrogens, non-steroidal molecules, due to their structure similar to that of estrogens
(Figure 5), could be used for HRT in post-menopausal women and cancer prevention in both pre-
and postmenopausal women [2,133]. However, the use of phytoestrogens has not been strongly
recommended due to lack of and contradiction between available data [134,135]. Additionally, critical
papers considered administration of phytoestrogens contraindicated in patients who survived breast
cancer [136]. A possible explanation for the cancer preventive action phytoestrogens/polyphenols
is the existence of the two types of estrogen receptors: ERα and ERβ. It was noticed that estradiol
particularly binds ERα, while phytoestrogens (like, genistein) bind ERβ. Phytoestrogens rather
behave as selective estrogen receptor modulators, with agonistic effects in the uterus and bones, but
antagonistic effect in the mammary tissue. Since the function of ERα and ERβ in breast tumor cells
was associated with activation and suppression of proliferation, respectively, the selective effect can
account for their utility in HRT [137].
Molecules 2015, 20, page–page 
14 
late apoptosis confirmed by nuclear accumulation of p53 and p21 [109]. To sum up, polyphenols under 
different environmental conditions may induce processes associated with early or late apoptosis, 
decreased expression of anti-apoptotic proteins and increased expression of the pro-apoptotic ones. 
However, most of the concentrations applied in in vitro studies are high and this may represent a 
drawback for clinical applications. Additional studies with physiological concentrations administrated 
for a longer time or animal experiments to check the toxicity of polyphenols at higher concentrations 
will help us understand the utility of polyphenols in practice. 
4.5. Estrogen Receptors and Polyphenols 
Estrogen hormones are thought to be key mediators for the development of the female 
reproductive system and for the progression of breast cancer [130,131]. Since it was noticed that estrogen 
administration was associated with breast cancer [132], it h s been proposed that phytoestrogens, 
non-steroidal molecules, due to their structure similar to that of estrogens (Figure 5), could be used for 
HRT in post-menopausal women and cancer prevention in both pre- and postmenopausal women 
[2,133]. However, the use of phytoestrogens has not been strongly recommended due to lack of and 
contradiction between available data [134,135]. Additionally, critic l papers considered administration 
of phytoestrogens contraindicated in patients who survived breast cancer [136]. A possible explanation 
for the cancer preventive action phytoestrogens/polyphenols is the existence of the two types of estrogen 
receptors: ERα and ERβ. It was noticed that estradiol particularly binds ERα, while phytoestrogens 
(like, genistein) bind ERβ. Ph toe trogens rath r behave as selective estrogen receptor modulator , 
with agonistic effects in the uterus and bones, but antagonistic effect in the mammary tissue. Since 
the function of ERα and ERβ in breast tumor cells was associated with activation and suppression of 
proliferation, respectively, the selective effect can account for their utility in HRT [137]. 
 
Figure 5. Chemical structure of 17β-estradiol and phytoestrogens [134,138]. 
There are several mechanisms of estrogen action at the cellular level (Figure 6): (i) ligand-dependent 
action through nuclear steroid receptor family; (ii) ligand-independent action through the impact of 
intracellular kinases on the phosphorylation of nuclear estrogen receptors; (iii) estrogen response 
element (ERE)-independent action of activated nuclear estrogen receptors on the transcription of genes 
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There are several mechanisms of estrogen action at the cellular level (Figure 6):
(i) ligand-dep ndent action through nuclear steroid r ceptor family; (i ) ligand-independent
action through the impact of intracellular kinases on the phosphorylation of nuclear estrogen receptors;
(iii) estrogen response element (ERE)-independent action of activated nuclear estrogen receptors on
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the transcription of genes containing alternative response elements; (iv) non-genomic mechanism
trough cell-surface ER connected to intracellular signaling pathways [139]. Cell proliferation and
survival can be triggered by ER through genomic activity and in correlation with signaling pathways
of receptor tyrosine kinase (RTK) families: EGFR and IGFR. The intracellular signaling pathways
responsible for the collaboration between cell-surface ER and RTK are: (i) the mitogen-activated
protein kinase (MAPK) pathway including rat sarcoma virus protein homolog (Ras), virus-induced
rapidly accelerated fibrosarcoma protein homolog (Raf), MAPK/extracellular signal-regulated
protein kinase (ERK) kinase (MEK) and ERK signaling proteins (Ras/Raf/MEK/ERK pathway);
(ii) the PI3K/Akt/mammalian target of rapamycin (mTOR) signaling pathway [2,21,35,132,140,141].
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activating protein-1 (AP-1) transcription factors and (ii) cell surface activity of plasma membrane ER 
in connection with growth factor receptor signaling pathways [21,139]. Nuclear ER activity might be 
inhibited by genistein and resveratrol; the expression or phosphorylation of EGFR family can be 
downregulated by curcumin, resveratrol, quercetin and genistein; ERK phosphorylation can be reduced 
by curcumin; PI3K activity can be inhibited by EGCG and genistein, while Akt action can be inhibited 
by EGCG, genistein and apigenin [142–149]. Blue and red lines indicate stimulation and inhibition, 
respectively (for the sake of simplicity only the major proteins of the signaling pathways were included). 
Some flavonoids like genistein, daidzein and quercetin are known to exert anti-oxidant, anti-tumor 
and anti-inflammatory effects through their ability to scavenge free radicals [150] and through their 
capacity to mimic the effect of estrogens in physiological activities [151]. Administration of 10 µM 
genistein for 6 days bound to estrogen receptors in MCF-7 cells with a dissociation constant (Kd) of  
4 nM and modulated the expression of proteins regulated by ER. Resveratrol influenced the mRNA 
expression of genes involved in ER signaling pathways with a higher activity in ER+ than ER- breast 
cancer cells [152]. Additional data about resveratrol indicates that it may activate other pathways 
Figure 6. The effect of polyphenols on nuclear ER, HER2 and IGF signaling pathways. Two main
mechanisms of E2 action are depicted: (i) genomic activity of nuclear ER in connection with ERE or
activating prot in-1 (AP-1) transcription factors a d (ii) cell surface activity of plasma membrane ER
in connection with rowth factor r ceptor signaling pathways [21,139]. Nuclear ER activity might
be inhibited by genistein and resveratrol; the expression or phosphorylation of EGFR family can
be downregulated by curcumin, resveratrol, quercetin and genistein; ERK phosphorylation can be
reduced by curcumin; PI3K activity can be inhibited by EGCG and genistein, while Akt action can
be inhibited by EGCG, genistein and apigenin [142–149]. Blue and red lines indicate stimulation and
inhibition, respectively (for the sake of simplicity only the major prot ins of the sig ali g pathways
were included).
Some flavonoids like genistein, daidzein and quercetin are known to exert anti-oxidant, anti-tumor
and anti-inflammatory ffects through their ability to scavenge free radicals [150] and through their
capacity to mimic the effect of estrogens in physiological activities [151]. Administration of 10 µM
genistein for 6 days bound to estrogen receptors in MCF-7 cells with a dissociation constant (Kd)
of 4 nM and modulated the expression of proteins regulated by ER. Resveratrol influenced the
mRNA expression of genes involved in ER signaling pathways with a higher activity in ER+ than
ER- breast cancer cells [152]. Additional data about resveratrol indicates that it may activate other
pathways independent of ER which are responsible for cell growth inhibition, but it is an ER agonist
at low doses (10´11–10´8 M) [153]. A new theory was put forward by Zeng and coworkers who
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suggested that up-regulation of ERα in ER negative cell lines may be further utilized to increase
sensitivity to anti-hormone therapy [154]. Hence, physiological concentrations of EGCG (0.1–1 µM)
were administrated for 48 h to three cancer cell lines and one control breast cell line. In MCF-7 cell line
downregulation of ERα was observed, in MDA-MB-231 and T47D cell lines was noticed the increased
in ERα, while no detectable changes were identified in MCF-10A control cell line. Further, to confirm
their hypothesis, MDA-MB-231 and T47D were treated with EGCG followed by tamoxifen which
indeed lead to reduction in cell proliferation [154].
4.6. Effect of Polyphenols on Plasma Membrane Receptors and on Signaling Pathways
The effect of polyphenols on intracellular signaling pathways may be a direct effect on kinases
and transcription factors or preceded by polyphenol-induced alterations in the activity of membrane
receptors (Figure 6). EGCG at concentration of 80 µg/mL was found to inhibit HER2 tyrosine
phosphorylation almost completely in mouse mammary tumor virus (MMTV)-HER2 NF639 cell
line [144]. Also, exposure of BT474 breast cancer cells to 25 µM genistein for 3 days reduced the
expression level of EGFR, HER2 and HER3 [146]. The level of HER2 protein was decreased in a
time- and dose-dependent manner in SK-BR-3 breast cancer cells by administration of 100 and 200 µM
quercetin due to poly-ubiquitination of HER2 [145]. The inhibitory activity of curcumin was mainly
observed on EGFR. It downregulated EGFR and p-EGFR levels in MCF-7 cells [155], reduced the
phosphorylation of EGFR in MDA-MB-231 (ER´/PR´/HER2´/EGFR+) breast cancer cells [148]
and interrupted the association between α6β4 integrin and EGFR by blocking the distribution α6β4
integrin into lipid rafts [142]. The effect of resveratrol was studied in MCF-7, MDA-MB-231 and
SK-BR-3 breast cancer cell lines. In MCF-7 cell line, 10 and 40 µM resveratrol applied for 24 h reduced
the cell surface expression of EGFR [143]; in MDA-MB-231 breast cancer cell line resveratrol suppressed
EGF-mediated migration and matrix metalloproteinase (MMP)-9 levels [156]; in SK-BR-3 breast cancer
cell line resveratrol mediated downregulation of HER2 gene [157]. On the contrary, low concentrations
of genistein (1 µM) stimulated the growth of MCF-7 breast cancer cells and increased the expression of
IGF-1 receptor. An estrogen receptor antagonist blocked the upregulation of IGF-1 receptor expression
induced by genistein, supporting the hypothesis that the effect of genistein on IGF-1 receptor required
the communication between IGF-1 receptor and ER pathways [158,159]. The stimulatory effect of
genistein may be related to its structural similarity to estrogen and its agonistic effect on estrogen
receptor [160]. In addition to the specific effects on membrane receptors polyphenols may alter the
structure of lipid rafts. It has been shown that EGCG caused a reduction in the amount of detergent
resistant membranes in SK-BR-3 cell line [127].
Cells communicate with each other using signaling molecules which in turn activate intracellular
pathways. Most intracellular proteins involved in signaling are kinases which are intensely altered in
breast cancer cells and part of these alterations have been related to drug resistance [161,162]. It was
shown that EGCG is able to inhibit several signaling pathways. While short-term (24 h) exposure to
40 µg/mL EGCG led to partial inhibition of the PI3K-Akt pathway, promoting cell survival [144], the
long-term (two weeks) presence of EGCG in MMTV-HER2 NF639 cell culture medium induced the
activation MAPK pathway and resistance to EGCG [163].
The adrenergic system in the human body is associated with stress signaling, which in turn triggers
the production of ROS and their production in high quantities can lead to cancer development [164–166].
MDA-MB-231 human breast cancer cells expressing β2-adrenergic receptor (β2-AR) were treated with
0.1, 1 and 10 µM quercetin-3-Oglucuronide (Q3G), a circulating metabolite of quercetin, for 24 h. The
quercetin metabolite suppressed cAMP production and Ras activation accompanied by a reduction in
the level of ROS. All these results suggested that Q3G may be used as a dietary chemo-preventive
factor against stress-related breast cancer [167].
Wingless/integration 1 (Wnt) signaling was associated with cancer progression and elevated levels
of β-catenin, the central protein responsible for the activation of the canonical Wnt pathway [168–170].
The Wnt pathway was suggested to be involved in the epithelial-mesenchymal transition (EMT) and
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its suppression may inhibit EMT and metastasis [171]. Flow cytometric analysis of MCF-7 breast cancer
cells revealed a significant inhibition of Wnt signaling by 10 µM curcumin applied for 12 h [172].
In another breast cancer cell line, MDA-MB-231 (ER´/PR´/HER2´, EGFR+), a model for
triple negative breast cancer, administration of 30 µM curcumin for 48 h reduced phosphorylation
of ERK [148]. Apigenin was shown to have a multitude of effects on MCF-7 breast cancer cells. It
blocked the activities of MAPK, protein kinase A (PKA), p38, Akt suggesting that apigenin might act
as a protein kinase inhibitor. Moreover, the administration of 5, 10 and 20 µM apigenin decreased E26
transformation-specific domain-containing protein (Elk1), cAMP response element-binding protein
(CREB) and CCAAT-enhancer-binding protein homologous protein (CHOP) levels in MDA-MB-231
breast cancer cells indicating that apigenin may act as an inhibitor of the transcription factors [149]. The
potential role of apigenin as an anti-cancer agent was confirmed in HER2-overexpressing MCF-7 cells in
which apigenin reduced tyrosine phosphorylation of HER2 and reduced expression of phosphorylated
Janus kinase 1 (phospho-JAK1) and phospho-STAT3 [173]. In conclusion, several polyphenols (EGCG,
genistein, quercetin, curcumin and resveratrol) successfully reduced the phosphorylation or expression
level of EGFR family members in the micromolar concentration range. However, low, physiological
concentrations of genistein led to increased IGF1R expression associated with cell proliferation. On the
other hand, polyphenols reduced the level of Wnt, a molecule involved in EMT suggesting that they
may inhibit the metastastic process. The antiproliferative effect of polyphenols was caused by their
ability to inhibit the phosphorylation of key signaling molecules (MAPK, PKA, p38, Akt, Elk, JAK1
and STAT3). Taken together, these results support the pleiotropic effect of natural molecules against
malignant transformation.
4.7. Epigenetic Mechanisms and Polyphenols
Epigenetic changes are heritable modifications which do not involve changes in the nucleotide
sequence of DNA, but still induce alterations in the phenotype. These changes in gene expression may
occur during development, differentiation and also may be due to the impact of the environment on the
organisms [16,174–178]. At the biochemical level three main epigenetic modifications are known: DNA
methylation, histone modification and microRNA (miRNA) expression. DNA methylation. Methylation
of genes takes place in cytosine-phosphate-guanine (CpG) island of the promoter region leading to
silenced gene expression. Five members of DNA methyltransferases (DNMT) exist in mammals:
DNMT1, DNMT2, DNMT3α, DNMT3β, and DNMT3L. Tumor progression is regularly correlated with
hypermethylation of tumor suppressor genes. Histone modification. Positively charged lysine residues
in histones are responsible for the attraction between the nucleosomal core and negatively charged
DNA leading to condensation of the chromatin (heterochromatin) and inhibited gene transcription. On
the contrary, addition of an acetyl group to histones by histone acetylases/histone acethyltransferases
(HAT) will remove the positive charge and the chromatin will display a loose structure (euchromatin)
which will facilitate gene transcription. Since acetylation is a reversible phenomenon, the reverse
process is catalyzed by an enzyme, histone deacetylase (HDAC) which removes acetyl groups from
lysine and inhibits gene expression. Abnormal deacetylation of histones due to high activity of HDAC
correlated with silencing of the genes was observed in cancer cells. miRNA expression. Small regulatory
RNA may inhibit protein expression after binding to the target gene. Silencing, down-regulation
or dysregulation of miRNAs was reported in breast cancer [16,174,179,180]. Compared to genetic
changes the epigenetic modifications are considered reversible [180]. In breast cancer samples DNMT1,
DNMT3A, DNMT3B levels were increased 1.8–2.9 fold compared to normal tissue [179], tumor
suppressor proteins: cyclin-dependent kinase inhibitor p16 which inhibit Cdk4 (p16INK4a) and
alternate reading frame p14 protein (p14ARF) were inactivated [181], while the BRCA1 gene was
epigenetically silenced and deleted [182]. The expression of several DNA methyl transferases (DNMT1,
DNMT3a, and DNMT3b) has been found to be elevated in breast cancer tissue. Since several natural
compounds (EGCG, genistein, withaferin A, curcumin and resveratrol) have been reported to decrease
this elevated transcription of DNMT1, DNMT3a, and DNMT3b genes, the lower incidence of breast
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cancer among Asian women, who consume more of these natural compounds, may be related to the
demethylation potential of these polyphenols [16,183].
Normal cells undergo senescence by losing 150–300 bp from their telomeres with each cell division.
In cancer cells this phenomenon is avoided by enzymes called telomerases. Telomerases have a low
activity in normal cells, but they were identified as being highly active in 90% of cancers. The catalytic
subunit of telomerase is human telomerase reverse transcriptase (hTERT). The actual paradigm which
supports the idea that promoter hypermethylation represses gene transcription [184] was challenged by
the observation that hypermethylation of hTERT promoter was associated with increased expression
of telomerase in cells [185,186]. EGCG treatment of MCF-7 cells inhibited the activity of DNMT1
leading to hypomethylation of hTERT followed by reduced hTERT transcription [187]. Similarly,
genistein inhibited the transcription of hTERT, downregulated DNMT1, DNMT3a, DNMT3b [188].
Although much less data is available about the effect of polyphenols on miRNA (miR) expression,
it has been reported that 10 to 60 µM curcumin upregulated miR-15 and miR-16 transcript levels in
MCF-7 cells associated with reduced expression of Bcl-2, one of the anti-apoptotic proteins [189]. In
conclusion, polyphenols like EGCG, genistein, curcumin and resveratrol downregulated the expression
of DNA methyl transferases in breast cancer cell lines. Nevertheless, the scarcity of the data urges us to
investigate the epigenetic modifications induced by polyphenols further, particularly since epigenetic
changes are reversible compared to genetic modifications considered to be irreversible processes.
4.8. Breast Cancer Stem Cells (BCSC) and Polyphenols
The concept of cancer stem cells suggests that certain tumor cells are capable of self-renewal
similar to normal proliferative tissues (skin epithelium, intestinal epithelium or bone marrow) [190].
Opposed to leukemic stem cells which can be identified by markers such as CD34 and CD38, cancer
stem cells from solid tumors are poorly characterized. CD24´ and CD44+ cells have been putatively
identified as breast cancer stem cells [190,191]. The anti-cancer effects of resveratrol were studied
in CD24´/CD44+/epithelial specific antigen (ESA)+ populations of cancer stem cells selected from
MCF-7 and MDA-MB-231 breast cancer cell lines. Exposure of the breast cancer stem cells to 50 and
100 µM resveratrol for 72 h reduced cell viability and mammosphere formation, induced apoptosis
and reduced lipid synthesis confirmed by down-regulation of fatty acid synthase (FAS) [192].
Administration of 40 to 160 µg/mL EGCG induced cell death and reduced mammosphere
formation in stem-like SUM-149 cells selected from SUM-149 inflammatory breast cancer cell lines
associated with very aggressive phenotype [193]. Cancer stem cells with a CD44+/CD24´{low
phenotype were isolated from two other breast cancer cell lines (MCF-7 and T47D). Exposure of
breast cancer stem cells to 5 to 20 µM curcumin for 24 h inhibited migration and mammosphere
formation, increased the expression of the epithelial markers cytokeratin 18 and 19, while decreasing
the expression of Cyclin D1, avian myelocytomatosis viral oncoprotein homolog (c-myc), vimentin,
MMP-2,-9 and the nuclear localization of β-catenin [194]. These results suggest that polyphenols have
an inhibitory effect on cancer stem cells.
4.9. EMT and Polyphenols
Epithelial mesenchymal transition has been described as a process in which cells in normal
and tumor tissues migrate and invade other tissues. At the beginning of EMT the expression of
the epithelial markers (E-cadherin and γ-catenin) is downregulated, while mesenchymal markers
such as MMP-2, and -9, fibronectin, vimentin are up-regulated. The entire transformation of the
cells will provide them with a new phenotype which will allow them to migrate and invade
the surrounding environment, an essential step in metastasis formation. After reaching the
target tissue, the cells will undergo a reversal process, a mesenchymal-epithelial transition (MET)
characterized by the upregulation of epithelial markers [195,196]. Exposure to 20 µM curcumin for
48 h decreased the expression of vimentin, increased the expression of E-cadherin, inhibited cell
motility and invasiveness in MCF-7, MDA-MB-231 breast cancer cells exposed to lipopolysaccharide
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(LPS) in order to trigger EMT [197]. Exposure of MCF-7 breast cancer cells to environmental
carcinogens: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), benzo[a]pyrene (B[a]P) and
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) increased the expression of the EMT markers
MMP-9 and vimentin while diminishing the level of E-cadherin. Treatment of the transformed
cells with 10 and 20 µM EGCG attenuated EMT characteristics [47]. Dimethylbenz[a]anthracene
(DMBA)-induced mouse mammary adenocarcinoma cell lines displayed decreased level of E-cadherin
which was up-regulated by 60 µg/mL EGCG [198]. The EMT phenotype in EGF-treated MCF-7 cells
characterized by low E-cadherin, γ-catenin and increased vimentin, fibronectin, N-cadherin expression
was normalized and enhanced migration was inhibited by treatment with resveratrol [199,200]. It can
be concluded that polyphenols revert the process of EMT and are, therefore, expected to decrease the
metastatic potential of cancers.
4.10. Administration of Polyphenols as Nanoparticles
Since the toxicity of chemotherapy requires strategies to reduce its side effects, administration
of conventional chemotherapeutic agents in nanoparticles and their combination with polyphenols
emerge as a novel modality in breast cancer therapy. Moreover, the low level of stability of polyphenols
compromising their bioavailability requires a new approach to increase intracellular stability and
constant release of the compounds [201]. In a recent, complex study Narayanan and coworkers
observed that combination nanoparticles containing EGCG and paclitaxel increased apoptosis,
inhibited NF-κB activation, down-regulated the major genes involved in metastasis, angiogenesis and
cell survival in MDA-MB-231 cells. These effects were significantly enhanced when the nanoparticles
were targeted with anti-EGFR antibodies. At the same time, multidrug resistance developed in
MDA-MB-231 cells was inhibited by EGCG-containing nanoparticles shown by downregulated
P-glycoprotein expression. Moreover, the effect of combination nanoparticles containing EGCG
and paclitaxel was tested in samples from patients with breast cancer and their effectiveness was
found to be correlated with high Ki-67 proliferation index [201]. The stability, sustained release,
intracellular concentration of EGCG was increased if it was loaded into liposomes or chitosan-coated
liposomes. Both types of nanoparticles were superior to free EGCG in reducing cell viability and
inducing apoptosis [202]. Encapsulating quercetin in methoxypolyethylene glycol-polylactic acid
(MPEG-PLA) is a modality to defeat its hydrophobicity. Quercetin nanoparticles with 155 nm size
induced apoptosis in a triple negative cell model of breast cancer, MDA-MB-231 cell line, with the drug
being released for 10 days [203]. An improved system of targeted nanoparticles with polyphenols
displaying higher selectivity was presented by Catania and coworkers who showed that curcumin
and resveratrol-containing liposomes coupled to anti-HER2 antibodies had enhanced cellular uptake,
cytotoxic and antiproliferative effects mainly in the breast cancer cell line with the highest expression
of HER2 [204]. In order to increase the stability and longer retention of polyphenols inside of the
cells, curcumin and polylactic-co-glycolic acid (PLGA) nanoparticles were prepared. The exposure
of MCF-7 cells to nanoparticles inhibited cell proliferation, induced apoptosis, released curcumin for
10 days in vitro and blocked the cell cycle in the S and G2/M phases [205]. The results beginning to
emerge establish that encapsulation of polyphenols into nanoparticles increases their bioavailability
and effectiveness. However, additional data are required in order to demonstrate that polyphenols
reduce the cytotoxicity of conventional chemotherapy in breast cancer cells.
4.11. Combined Applications of Polyphenols in Vitro
Polyphenols have multiple beneficial effects in cardiovascular and neurodegenerative diseases
as well as in cancer, but their poor bioavailability together with rapid degradation, metabolization
and excretion is a significant obstacle to their successful application. This drawback can be overcome
by combining different polyphenols or to associate polyphenols with allopathic therapy [28]. The
effect of combined EGCG and curcumin was studied in doxorubicin resistant MCF-7 breast cancer
cells. EGCG alone induced growth inhibition, apoptosis, while curcumin alone inhibited the function
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of P-glycoprotein. Exposure to the combination of EGCG and curcumin enhanced the toxicity of
doxorubicin in MCF-7 cells [206]. Synergistic cytotoxic effects and arrest of the cells in the G2/M phase
was observed for the same polyphenol combination in MDA-MB-231 breast cancer cells [207]. TNBC
is notorious for its therapy resistance [208–211]. A dual approach, targeting mutant p53 by siRNA
and administration of EGCG, a polyphenol frequently reported to have pro-apoptotic properties,
has been studied in a TNBC cell line (Hs578T) expressing mutant p53. The combination of p53
small interfering RNA (siRNA) and EGCG increased apoptosis more than any treatment alone. The
results reinforced the idea that multi-targeted therapy will enhance the anti-cancer effect in a cell line
model of TNBC [212]. Administration of resveratrol, Herceptin and combination of resveratrol with
Herceptin was investigated in MCF-7 and T47D breast cancer cell lines. Combination of resveratrol and
Herceptin reduced cell growth and HER2 expression in both cell lines and increased subG1 fraction
compared to control samples or each treatment applied alone [213]. However, administration of
resveratrol decreased cell death induced by paclitaxel in MDA-MB-231 and SK-BR-3, but not in MCF-7
breast cancer cells [214]. Attention must be paid to genistein in combination with other drugs. The
combinatorial effect of cisplatin, paclitaxel or tamoxifen with genistein was studied in breast cancer
cell lines with different ERα/ERβ ratio: MCF-7 (high ratio), T47D (low ratio), MCF-7 overexpressing
ERβ. Combination of cisplatin with genistein or tamoxifen with genistein decreased ROS production,
apoptosis and autophagy in MCF-7 cells, but not in T47D and MCF-7 overexpressing ERβ, suggesting
that in breast cancers with high ERα/ERβ ratio administration or consumption of genistein may be
harmful [111].
5. In Vivo Experiments
5.1. The Effect of Polyphenols on Tumor Growth—Animal Models
Since the administration of hormones in HRT may promote late stages of carcinogenesis
in postmenopausal women, different strategies have been proposed to alleviate postmenopausal
symptoms, to inhibit osteoporosis and to prevent heart diseases and a possible solution might be the
administration of natural compounds [130]. However, the inconsistency and contradictory results
should warn us to interpret these data carefully [136,215].
Earlier in vivo result communicated the beneficial effect of genistein administrated to pre-pubertal
Sprague-Dawley rats with DMBA induced tumors; accordingly, reduction in carcinoma incidence,
reduction in tumor multiplicity, upregulation of BRCA1 mRNA was reported in correlation of
genistein administration in rats with chemical induction of breast carcinoma [216,217]. In a transgenic
mouse model of breast cancer (mouse mammary tumor virus-neu (MMTV-neu) transgenic mice)
administration of genistein decreased the mammary tumor latency compared to control group [217].
On the other hand, an entire series of papers published by Helferich and co-workers warn us about
the effects of genistein in ovariectomized athymic mice. The data from these papers reported increased
tumor size in dose-dependent manner, increased cell proliferation and increased expression of pS2,
an estrogen responsive gene; moreover, genistein annulated the effect of tamoxifen and increase
progesterone and cyclin D1 levels [218,219]. Likewise, adult female Sprague-Dawley female rats
with chemical induction of breast tumors, after the exposure to genistein displayed increased tumor
cross-sectional area, increased tumor multiplicity, but no effect on tumor incidence compared to control
rats [220]. The data reported about administration of genistein in animal models of breast cancer
are contradictory (Table 3), since earlier papers indicated a beneficial effect of genistein, while later
publications associate administration of genistein with increased incidence of breast cancer. These
inconsistencies might be explained by various factors: (i) the animal models reported are highly
different, from chemically-induced breast cancer in rats to transgenic mice or nude mice with human
xenograft tumor; (ii) the doses and the periods used for the administration of genistein are highly
heterogeneous and make the reports difficult to be compared; (iii) each experiment report other output
parameters; and (iv) the toxicity of the polyphenols was not always taken in account.
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Table 3. Summary of in vivo experiments: breast cancer and polyphenols.
Author, Year Animals Dose and Duration of Administration Result
Genistein
Murrill W.B. et al., 1996 [216] Pre-pubertal Sprague-Dawley rats with DMBA inducedcarcinoma 500 µg/g body weight in P16, P18, P20 Reduction in carcinoma incidence
Jin Z. et al., 2002 [217] Pre-pubertal rats with DMBA induced carcinoma 500 mg/kg body weight in P7, P20 Reduction in tumor multiplicity by 60%
Cabanes A. et al., 2004 [221] Pre-pubertal female rats with DMBAinduced carcinoma 50 µg (injection) daily from P7 to P20
Reduction in the size of the mammary epithelial area,
reduction in number of TEB, increased density of
lobulo-alveolar structures (increased differentiation),
up-regulation of breast cancer tumor suppressor gene 1
(BRCA1) mRNA
Ju Y.H. et al., 2001 [218] Ovariectomized athymic mice with MCF-7 xenografts 125, 1000 µg/g body weight in the diet for 22 weeks
Tumor size was increased in dose-dependent manner; cell
proliferation was enhanced at concentration >250 µg/g;
increased in pS2, an estrogen responsive gene at
concentration >500 µg/g
Ju Y.H. et al., 2002 [219] Ovariectomized athymic BALB/c (nude) mice withMCF-7 xenografts 1000 ppm (1000 µg/g body weight)
Genistein canceled the inhibitory effect of tamoxifen,
decreased estradiol level in plasma, increased expression
estradiol regulated genes (pS2, progesterone, cyclin D1)
Jin Z. et al., 2002 [217] Transgenic mice for MMTV-neu gene 250 mg/kg for 7 weeks Mammary tumor latency delayed compared to controls; noreduction in in the number or tumor size
Kijkuokool P. et al., 2006 [220] Adult female Sprague-Dawley rats exposed to NMU 1 mg/kg body weight daily subcutaneous injectionfor 20 weeks
Increased tumor cross-sectional area, increased tumor
multiplicity, but not tumor incidence
Daidzein
Constantinou A.I. et al., 2001 [222] Female Sprague-Dawley rats with DMBA breastcarcinoma induction 200 mg/kg diet
Tumor incidence and survival similar to control groups;
reduction in tumor multiplicity by 32%; increased median
tumor latency
Jin Z. et al., 2002 [217] Transgenic mice for MMTV-neu gene 250 mg/kg for 7 weeks Mammary tumor latency delayed compared to controls; noreduction in in the number or tumor size
Lamartiniere C.A. et al., 2002 [223] Virgin female rats 250 and 1000 mg/kg in the diet, 2 weeks prior tobreeding till 50 day postpartum
Moderate reduction in ovarian and uterine weights and
mammary gland size; reduced body weight; reduction in
circulating progesterone
Ju Y.H. et al., 2006 [224] Ovariectomized athymic mice with MCF-7 humanxenografts 125 to 1000 ppm (125 to 1000 µg/g body weight)
No statistical significant reduction in tumor size
and proliferation
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Table 3. Cont.
Author, Year Animals Dose and Duration of Administration Result
Resveratrol
Banerjee S. et al., 2002 [225] Female Sprague-Dawley rats with DMBA breastcarcinoma induction 10 ppm
Reduction in the incidence (by 45%) and multiplicity (by 55%)
of the tumors; increased latency period; suppressed COX-2,
MMP-9, NF-kB; no effect on body weight or tumor volume
Whitsett T. et al., 2006 [226] Female Sprague-Dawley rats with DMBA breastcarcinoma induction 1 g/kg in the diet
Suppression of mammary carcionogenesis: less number of
tumors per rat, longer tumor latency; reduced proliferation;
increased apoptosis in epithelial cells of TEB; reduced
toxicity: no alterations in body weight
Singh B. et al., 2014 [129] August Copenhagen Irish rats (rodent model of breastcarcionogenesis) 50 mg subcutaneous pellet per month, 8 months
Decreased tumor incidence and increases latency in
mammary tumors induced by estradiol; upregulated NRF2, a
regulator of the anti-oxidant response; induced apoptosis
(increased p53 and PARP cleavage) in mammary tissue
EGCG
Whitsett T. et al., 2006 [226] Female Sprague Dawley rats with DMBA and NMUmammary cancer induction 0.065% in the drinking water
Not efficient in reduction of breast cancer incidence
at these doses
Quercetin
Verma A.K. et al., 1998 [227] Female Sprague Dawley rats with DMBA and NMUmammary cancer induction 5% in the diet
Reduction in the number of tumors; decreased tumor
multiplicity; no detectable signs of toxicity (similar body
weight in treated and control rats)
Singh B. et al., 2010 [228] Female August Copenhagen Irish (ACI) rats 2.5 g/kg in diet, 8 months
No induction of tumors in ACI rats; did not protect against
estrogen-induced tumors; did not confer protection against
breast cancer and may worsen breast cancer status regularly
exposed to estradiol
Curcumin
Masuelli L. et al., 2013 [121] BALB-neuT transgenic mice for neu oncogene n.m.
Increased tumor-free survival; reduction in tumor
multiplicity; safe to be administrated: no modification in
hematological and clinical chemistry parameters
Abbreviations: P, postnatal day; DMBA, 7,12-dimethylbenz(a)antracen; TEB, terminal end buds; BRCA1, breast cancer tumor suppressor gene 1; Nrf2, nuclear factor-erythroid 2-related
factor-2; NMU, N-methyl-N-nitrosourea; ppm, parts per million; MMTV, mouse mammary tumor virus; n.m., not mentioned.
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Both identification/generation of the animal models comparable to human disease and systematic
investigation of parameters still remain a challenge for the scientific world. The effect of daidzein,
another polyphenol with phytoestrogen characteristics, was investigated in different animal models
ranging from breast cancer in mice transgenic for neu oncogene to chemically induced breast cancer and
human xenograft tumors. In Neu-transgenic mice, mammary tumor latency was delayed by daidzein
and a 32% reduction in tumor multiplicity was noticed in chemically induced breast cancer [222].
However, administration of daidzein in ovariectomized athymic mice induced no significant changes
in tumor size and proliferation [224]. The toxicity of daidzein on the reproductive tract of virgin female
rats was investigated by Lamartiniere and co-workers. The authors reported moderate reduction
in ovarian and uterine weights, slight reduction in mammary gland size and decreased levels of
circulating progesterone [223].
The experiments on female Sprague-Dawley rats with chemical breast cancer induction
demonstrated that administration of resveratrol reduced the incidence and multiplicity of the tumors,
increased the latency period, suppressed COX-2, MMP-9 and NF-κB levels, increased apoptosis in
epithelial cells and did not modify the body weight [225,226]. Administration of resveratrol as a
subcutaneous pellet for eight months in a rodent model of breast carcionogenesis (August Copenhagen
Irish rats) decreased the tumor incidence, increased tumor latency and increased apoptosis in mammary
tissue [129]. Low doses of EGCG displayed reduced efficiency against breast cancer in female
Sprague-Dawley rats with chemical breast cancer induction [226].Former data about administration of
quercetin to female Sprague-Dawley rats with chemical induction of breast cancer reported reduction
in the number of tumor, decreased tumor multiplicity and no detectable signs of toxicity [227].
Nevertheless, more recent data reported that quercetin did not confer protection against breast cancer
and even worse, it might increase tumorigenesis in animals with chronical exposure to estrogen [228].
Recent data reported that curcumin increased tumor-free survival, reduced tumor multiplicity and
displayed no toxicity in BALB-neuT transgenic mice [121].
In conclusion, the majority of evidence supports the cancer-preventive effects of polyphenols,
although contradictory results have also been published.
5.2. Involvement of Polyphenols in Modulation of Metastasis and Angiogenesis
The overall survival rate of patients with breast cancer has improved as a result of early detection
of the disease [23]. However, dormant tumor cells are responsible for the development of distant
metastases or recurrent disease in 25%–45% of patients 10–15 years after the patient was considered
to be cured [22,23]. Data from animal models for metastasis treated with polyphenols offered some
promising results. The administration of resveratrol, quercetin, catechin (5 mg/kg) to nude mice
with MDA-MB-435 mammary tumors reduced tumor growth and metastasis formation [229]. In
another model of mouse breast cancer, BALB/c mice bearing 4T1 breast tumors were exposed to
resveratrol for 21 days. The polyphenol decreased the number of pulmonary nodules and the plasma
level of MMP-9 [230]. Genistein reduced the number of lung metastases 10-fold in a preclinical
xenograft model of breast cancer metastasis in which MDA-MB-435 human breast carcinoma cells
were implanted in the mammary fat pad of female nude mice (orthotopic tumor model) [231]. Data
reported very recently shed light on the effect of dendrosomal curcumin (supramolecular structures
which encapsulates repetitive branched molecules) in mice with 4T1 tumors. Exposure to 80 mg/kg
dendrosomal curcumin significantly increased the survival rate and decreased metastasis formation
accompanied by downregulated expression of NF-κB, VEGF, COX-2 and MMP-9 in the breast tumor
as well as in lung, brain, spleen and liver tissues [232]. Similarly, mice subcutaneously inoculated
with 4T1 mouse breast cancer cells were exposed to curcumin loaded into biodegradable micelles.
Curcumin inhibited the tumor growth and the formation of spontaneous pulmonary metastases,
prolonged survival of the mice and reduced angiogenesis [233]. However, Helferich’s group warned
us about the involvement of soy isoflavones in promoting the development of breast cancer [234]. In
an attempt to model bone micrometastasis female BALB/c mice were injected intra-tibially with 4T1
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mouse mammary cancer cells. A combination of 750 mg/kg soy isoflavones (genistein, daidzein and
equol) administrated 3 weeks before and after tumor inoculation increased the bone microtumors and
stimulated the formation of lung metastases [234]. In summary, although several lines of evidence
suggest that polyphenols can decrease the number of metastases, there are some data contradicting
these observations. Therefore the administration of polyphenols for metastasis prevention should be
carefully designed and the expected results double checked.
The size of tumors cannot extend beyond 1–2 mm without a proper vascular network [235].
Several modalities which trigger and support the angiogenetic process have been described, starting
from sprouting angiogenesis and vasculogenesis to the development of tumor cells which can mimic
endothelial cells or the generation of the endothelial cells originating from cancer stem cells [236].
VEGF family of growth factors and hypoxia have been identified as the main factors responsible for
the angiogenetic processes [237]. In order to block angiogenesis several drugs have been approved:
bevacizumab (Avastin), an antibody directed against VEGF and tyrosine kinase inhibitors (TKI) of
VEGFR, such as sorafenib and sunitinib [236,238]. Nevertheless, the side effects of antibody and TKI
treatment are difficult to control and some of the patients are refractory to these therapies [236]. In light
of the complex and controversial effects of available drugs research into the possible anti-angiogenic
effects of EGCG are warranted. Administration of EGCG (50–100 mg/kg/day) for 4 weeks reduced
tumor weight, decreased capillary density in the tumors, diminished tumor VEGF expression without
affecting body weight and angiogenesis in the heart in C57BL/6J mice with E0771 mouse breast
cancer cells implanted in the mammary gland fat pad [239]. However, the same polyphenol did not
influence microvessel density in a different animal model [240]. The influence of soy isoflavones on
angiogenesis was investigated in animal models and exposure of DMBA-induced mammary tumors to
genistein reduced microvascular density and plasma VEGF and increased plasma levels of endostatin,
an anti-angiogenic agent [241]. Likewise, 10 mg/kg/day genistein reduced angiogenesis in mice with
F3II mammary cancer cells [242]. The angiogenesis in nude mice with MDA-MB-231 breast cancer
cells was inhibited by resveratrol [243] and by curcumin [244]. To sum up, although there are some
slight contradictions, polyphenol treatment can reduce angiogenesis most of the time thereby slowing
down tumor growth.
5.3. Combined Administration of Polyphenols–In Vivo Studies
The beneficial effect of combining polyphenols with conventional drugs in in vitro experiments
laid the foundation for testing such treatments in animal models. Administration of Herceptin and
genistein in combination to athymic mice with BT474 breast tumor cells injected subcutaneously
decreased the tumor size to the same level as Herceptin alone, suggesting that genistein did not
improve the outcome in this type of experiment [245]. Nude mice with MCF-7 cells implanted in
the mammary fat pad were treated with genistein, tamoxifen and a combination of genistein and
tamoxifen. Reduction in tumor growth, increase in apoptosis index, decrease in proliferation index,
reduction in the number of vessels in tumors and decrease in estradiol levels were associated with
synergistic activity of genistein and tamoxifen. Additionally, administration of soy phytochemical
concentrate in combination with tamoxifen amplified the above mentioned effects, suggesting that
soy compounds might be used in prevention or/and treatment of estrogen breast cancers [146]. In
contrast with the previous data, Helferich and co-workers reported that inhibitory effect of tamoxifen in
ovariectomized athymic mice with MCF-7 xenograft tumors was abolished by genistein in the presence
of low levels of estrogen. This finding was confirmed by investigation of the combinatorial effect of
estrogen, tamoxifen and genistein on xenograft tumors in nude mice. Combinatorial administration of
estrogen, tamoxifen and genistein increased proliferation, decreased apoptosis, increased the levels
of cyclin D1 and progesterone receptors mRNA, suggesting that genistein consumption should be
recommended with precaution in breast cancer patients receiving tamoxifen [246]. However, a recent
review about the effect of soy on breast cancer in preclinical studies suggested that it is premature to
rush any conclusions about stimulatory effect of isoflavones on breast cancer and about their ability
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to abolish the effect of tamoxifen without understanding their mechanism of action at the molecular
level. Identification of the molecular targets of soy isoflavones in human disease will be necessary
before reaching any solid conclusions regarding the chemopreventive or therapeutic effect of soy
consumption in breast cancer [247].
Immunodeficient mice bearing patient-derived trastuzumab- and lapatinib-resistant HER2+ breast
tumors revealed that such refractory tumors respond well to the combination of pertuzumab and
EGCG suggested by a considerable reduction in tumor size and apoptosis identified in tumor sections
by the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method. The authors
attribute the synergistic effect of adding EGCG to the treatment protocol to its ability to block fatty
acid synthase [248]. Breast cancer xenografts injected into the mammary fat pad of athymic female
mice exposed to combined resveratrol, quercetin, catechin treatment responded well to the combined
therapy [249]. Combined administration of EGCG and curcumin (25 mg/kg/day and 200 mg/kg/day,
respectively) in athymic female mice implanted with MDA-MB-231 cells decreased tumor volume and
reduced VEGFR-1 expression in tumors [207]. Administration of EGCG in combination with taxol
in BALB/c mice injected subcutaneously with 4T1 mouse breast cancer cells significantly decreased
tumor growth and the number of lung metastasis, while exposure to EGCG or taxol alone had no
significant effect [250]. Another line of evidence for the efficiency of the combination of paclitaxel
and polyphenols was presented by Kang and coworkers who showed that paclitaxel and curcumin
decreased tumor cell proliferation, increased apoptosis and decreased expression of MMP-9 in a breast
cancer murine model with MDA-MB-231 cells [251]. However, administration of resveratrol after
paclitaxel treatment suppressed tumor cell death in athymic mice with MDA-MB-231 xenografts [214].
The results of experiments applying polyphenols in combination in vivo are in agreement with in vitro
studies and imply that polyphenols usually increase the efficiency of conventional drugs without
enhancing toxicity.
6. Clinical Implications of Polyphenols
6.1. Bioavailability of Polyphenols in Human Body
Bioavailability, according to the Federal Food, Drug and Cosmetic Act in the US represent “the
rate and extent to which the active ingredient or active moiety is absorbed from a drug product
and becomes available at the site of action” [252]. The mode of application must also be considered
when characterizing bioavailability. In the case of intravenous administration only the ability of
the host organism to metabolize the nutrient must be taken into account, while both metabolic and
digestive processing must be considered in the case of oral application [253,254]. The bioavailability of
polyphenols in humans is explained in great detail in two reviews published by Claudine Manach and
co-workers [30,255]. Table 4 presents the sources, the used doses, the plasma concentration and the
elimination half-life of polyphenols in the human body.
Table 4. Bioavailability of main polyphenols in the human body (adapted from Manach C. et al., [255]).
Source/Polyphenol Dose Concentration inPlasma (µM) Half-Life (h) Ref.
Onions 100 mg quercetin eq 7.6 10.9 [256]
Apples 107 mg quercetin eq 0.3 23.0 [257]
Quercetin 50 mg 0.29 15.0 [258]
Orange juice 126 mg hesperitin eq 2.2 2.2 [259]
Orange juice 23 mg narigerin eq 0.64 1.3 [259]
Grapefruit juice 199 mg narigerin eq 5.99 2.2 [259]
Chocolate (80 g) 164 mg epicatechin eq 0.7 1.9–2.3 [260]
Red wine (120 mL) 35 mg catechin eq 0.091 3.1 [261]
EGCG 800 mg 2.33 1.9–4.6 [262]
Soy beverage 0.6 mg/kg daidzein eq 0.3 3.4 [263]
Soy beverage 1 mg/kg genistein eq 0.65 7.9 [263]
Daidzein 50 mg 0.76 9.3 [264]
Genistein 50 mg 1.26 6.8 [264]
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Additional aspects should be taken into account when the availability of polyphenols in the human
body is discussed, since (i) in both in vitro and in vivo experiments the concentrations of polyphenols
are much higher than those reached in the biological target when dietary uptake of polyphenols
in humans is considered; (ii) the anti-cancer effects may be due to the glycosylated or methylated
metabolic products of polyphenols and not only to the aglycone alone; (iii) urinary excretion of
polyphenols may reflect their bioavailability, but also excretion through the bile must be taken into
account, e.g., in the case of EGCG and genistein; (iv) generation of some of the polyphenol metabolites
with anti-cancer effects depends on the microbial intestinal metabolism, dividing individuals into
“producer” and “non-producer” phenotypes; (v) some of the polyphenol metabolites display more
pronounced anti-cancer effects than the aglycone itself (i.e., equol, the metabolite of daidzein) [30,255].
6.2. Chemoprevention of Breast Cancer by Polyphenols in Humans
At the end of the review we would like to consider the cancer-preventive effects of dietary
polyphenols (Table 5). Since results of studies with genistein, the polyphenol studied the most, are
contradictory, three, strikingly different hypotheses have been put forward for the effect of soy diet in
humans: (i) there is an inverse correlation between soy intake and breast cancer; (ii) soy isoflavones
do not change the evolution of breast cancer; (iii) on the contrary, genistein may have the ability
to increase the proliferation of breast cancer tumors. The first proposition assuming a favorable
relationship between increased soy consumption and decreased breast cancer risk is supported by
the strongest lines of scientific evidence. The intake of soy food in adolescence (13–15 years old)
by Asian girls may reduce the risk of breast cancer during adulthood, since the breast tissue in
adolescence is exposed to various changes and becomes more sensitive [265]. An epidemiological
study of 501 breast cancer patients and 594 controls indicated that the intake of soy food in adolescence
(at least once per week) and in adult life was inversely and dose-dependently correlated with the risk
of breast cancer [265]. High soy consumption was associated with a slight reduction in breast cancer
risk with better results in premenopausal women compared to postmenopausal ones (evidence from
18 epidemiological studies) [215]. The conclusion regarding the relationship between soy consumption
and breast cancer seemed to be different between women in Asian and Western countries. Thus, soy
intake had minor protective activity in post-menopausal women from Western countries, while in
pre- and postmenopausal women in Asian countries it showed a protective effect [266,267]. However,
some reports support the association between high plasma levels of circulating genistein and reduction
of breast cancer in the Dutch population [268]. The decreased risk of breast cancer was associated
with two types of diet: (i) Japanese/Chinese diet (2–3 meals/day with 25–50 mg isoflavone each)
with the recommendation of more than 100 mg isoflavones in the case of breast cancer patients, since
there is no evidence for the adverse effect of soy consumption [269,270]; (ii) Mediterranean diet with
the recommendation of vegetables, fruits, fish and soy intake [271]. Attention must be paid to high
consumption of fat and alcohol, since both aliments increased the risk of breast cancer [270,271].
The following breast cancer markers have been considered valuable for the evaluation of the effect
of dietary polyphenols in humans: plasma hormone levels, breast tissue density (mammography),
proliferation index and estrogen concentration at the tumor site [272,273]. Nevertheless, the use of
biomarkers from breast tissue collected by fine-needle aspiration (proliferation index/Ki-67 and
concentration of hormones in the tumor) are more reliable than so called “surrogate” markers
like plasma hormone level and breast tissue density [274]. Still, additional biomarkers for the
modifications induced by isoflavones in breast cancer (genetic, metabolic, magnetic resonance imaging)
are necessary [138].
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Table 5. Summary of the association between breast cancer risk and soy intake.
Author, Year Date of Study Cases 1 Ctrl 1 Diet Dose 2 OR/HR/RR (95% CI) Conclusion
Liu X.O. et al.,
2014 [270] 1990–2013 9299 11,412
Soy (soy protein, soy
food, soya- bean milk)
1–8 times/week
12.9–500 mg/day 3 0.65 (0.43–0.99)
Soy intake was associate with
reduction in breast cancer risk
(Chinese women)
Nagata C.
et al., 2014 a [267] 1985–2005 2531 25,332
Soy (tofu, soybeans,
miso soup) 1–3 times/week
0.62 (0.38–1.01) to 1.59
(0.90–2.81)
Soy intake was associated with
moderate and strong reduction of
breast cancer in post-menopausal
Japanese women
Fritz H. et al.,
2013 b [269] 1992–2012 1830
c n.m. Soy (soy food, soyprotein, genistein, IF)
Soy 13.03–65.7 g/day
IF 7.48–62.68 mg/day
0.25 (0.10–0.61) to 1.19
(0.76–1.85)
Soy intake was associated with no
change and increase survival, no
change and decrease recurrence of
breast cancer in Chinese, Korean,
USA, Shanghai women, respectively
Guha N. et al.,
2009 [275] 1997–2000 1954
d n.m. Daidzein, genistein,glycetin
Daidzein 1.5–9.6 mg/day
0.1–7.8 µg/day
Genistein 2.2–13 mg/day
0.1–7 µg/day
Glycetin 8.2–15 µg/day
3.6–8.2 µg/day
Daidzein 0.71 (0.45–1.11) to
1.16 (0.81–1.68)
Genistein 0.72 (0.46–1.13) to
1.09 (0.76–1.58)
Glycetin 0.68 (0.46–1.01) to
1.01 (0.71–1.43)
Decreased risk of breast cancer
recurrence was associated with high
daidzein and glycetin intake in postM
women Women treated with
Tamoxifen presented 60% decrease in
breast cancer recurrence after
daidzein intake
Trock B.J.
et al., 2006 a [215] 1978–2004 7453 16,521 Soy protein and tofu
1–5 times/week
1.6–3.5 g/day
0.86 (0.75–0.99) preM
0.70 (0.58–0.85) postM
0.77 (0.60–0.98)
Increased soy intake was associated
with modest reduction in breast
cancer risk Inverse association
between soy exposure and breast
cancer risk in preM (“stronger”) and
postM women Caution with
interpreting the data due to high
heterogeneity of soy exposure
Wu A.H. et al.,
2002 [276] 1995–1998 501 594
Tofu—adolescence
IF—adult
1–3 times/month +4 times/week
>1.79–6.24 mg/1000 kcal
>12.68 mg/1000 kcal
0.75 (0.48–1.15)
0.51 (0.31–0.84)
0.76 (0.53–1.09)
0.51 (0.33–0.78)
High soy intake during adolescence
and adult life was associated with
reduced risk of breast cancer
(Chinese, Japanese, Filipino women
in Los Angeles)
Shu X.O. et al.,
2001 [265] 1996–1998 296 359
Soy food—13–15 years,
adolescence 5.4 g/day 0.51 (0.40–0.65)
Adolescent soy food intake was
inversely associated with breast
cancer risk
Legend: 1—for meta-analysis, the number of cases and controls were summed; 2—high degree of heterogeneity; 3—selection from maximal values presented in the analysis;
a—includes case control only; b—includes case control, nested case control, prospective cohort study; c—includes survivors, deaths, recurrences; d—breast cancer survivors 6.31 years
after the diagnosis—isoflavone intake and breast cancer recurrence was evaluate; Ctrl, controls; preM, premenopausal status; postM, postmenopausal status; OR, odds ratio; HR,
hazard ratio; RR, risk ratio; CI, confidence interval; n.m., not mentioned; wk, week; d, day; mo, months; IF, isoflavone.
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Observations from several clinical studies related to the administration of soy food to
pre-menopausal and post-menopausal women or post-menopausal breast cancer survivors for
1–2 years did not significantly change the breast cancer biomarkers [274]. Earlier reports indicated that
exposure to 45 mg isoflavones/day for a duration of 14 days in 48 women with benign or malignant
breast lesions increased proliferation rate of the breast epithelium and up-regulated progesterone
expression suggesting that short-term soy administration may increase cell proliferation [277]. The
interaction of daidzein with gut bacteria leads to equol production in approximately 30% of the
human population, and a direct correlation between equol production and low breast density was
observed [278]. A comparison between Caucasian and Asian women indicated that the American
Asian population may produce more equol compared to American Caucasian population, suggesting
different metabolizing pathways [279]. Decreased cancer recurrence in a cohort of 1954 postmenopausal
breast cancer survivor women was correlated with daidzein and glycetin intake compared to
no isoflavone consumption [275]. Inverse correlation between the risk of breast cancer and the
consumption of resveratrol from grapes, but not from wine, was observed in another study [280]. In
postmenopausal women the adipose tissue produces sex steroid hormones resulting in the correlation
between high adiposity and increased breast cancer risk [281]. Similarly, high adiposity was linked
to low levels of sex steroid hormone binding globulin (SHBG), a protein responsible for binding of
the sex steroid hormones, while up-regulation of SHBG level was associated with reduced risk of
breast cancer [282]. The risk of breast cancer was associated not only with the increased production of
estrogen, but also with the production of estrogen metabolites; thus, a reduced urinary ratio between
2-hydroxiestrone (2-OHE1) and 16α-hydroxiestrone (16α-OHE1), two estrogen metabolites, had been
associated with increased risk of breast cancer [283]. Administration of 1 mg/day resveratrol in 40
post-menopausal women with high body mass index increased the concentration of SHBG in the
plasma and that of 2-OHE1 in the urine suggesting that resveratrol may have promising effects in
post-menopausal overweight women [284]. However, the side effects including diarrhea, increased
serum cholesterol concentration, grade 4 elevation of liver enzymes (one subject) and grade 3 skin
rashes (2 subjects) must be taken into consideration [284]. Exposure of 39 adult women with increased
risk of breast cancer to 50 mg trans-resveratrol, twice/day decreased the methylation of Ras association
domain family-1α (RASSF-1α), a tumor suppressor gene [285]. A study regarding consumption of
EGCG (843 mg EGCG/day for 1 year) in 1075 post-menopausal women indicated that the intake
of green tea extract was well tolerated [286]. Studies on the effect of EGCG in 472 patients with
breast cancer revealed a decreased number of axillary lymph node metastases and a lower frequency
of recurrence in pre-menopausal women with stage I–II breast cancer, while no improvement was
observed in stage III breast cancer [287]. However, other data obtained with Japanese women contradict
the above observations since no correlation was found between the plasma levels of the tea polyphenols
and breast cancer risk [288]. Similarly, no significant association between intake of food rich in flavonols
(quercetin, kaempferol and myricetin) or flavones (apigenin and luteolin) and incidence of cancers
was identified in another study in which information about polyphenol consumption was obtained
by food-frequency questionnaires [74]. In conclusion, the contradictory results published about the
breast cancer-preventive effects of polyphenols may be related the multifactorial nature of the disease,
the differences in the investigated populations and in the amount and type of dietary polyphenols
consumed by the patients.
7. Conclusions and Further Progress
A rational life style with a reasonable level of stress, quality and moderate nutritional intake,
correlated with physical exercises plays an important role in the prevention of cancer [71]. An approach
similar to the aggressive chemoprevention of cardiovascular diseases might be accomplished for cancer
chemoprevention as well. Measurable risk factors, such as hypercholesterolemia and hypertension,
have been identified in cardiovascular disease and significant success have been achieved in eliminating
them by drugs that lower cholesterol levels and reduce blood pressure [1].
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Therefore, the challenge is to identify such measurable risk factors for breast cancer and remove
or diminish them. Possible examples without incurring high expenses are the consumption of Asian
and Mediterranean diets and eliminating or minimizing the exposure to risk factors like dietary
alcohol or fat. Moreover, regular consumption of vegetables and fruits rich in polyphenols could be
an alternative way in chemoprevention of cancer [2]. Cancer is frequently considered to be a chronic
disease implying that chronic administration of cancer preventive compounds is required in order
to inhibit carcinogenesis [1]. Again, administration of dietary polyphenols may represent one of the
possible approaches. A summary of pros and cons in case of polyphenols administration in breast
cancer is given in Table 6. Further in vitro experiments, studies using in vivo animal models and clinical
trials are required to improve our understanding of the mechanisms of action of polyphenols for their
proper application as chemo-preventive tools in breast cancer.
Table 6. Breast cancer: the pros and cons of polyphenols.
Pros Cons
‚ DNA protection by the anti-oxidant activity
against carcinogens
‚ Decreased glucose uptake in cancer cells
‚ Cell cycle arrest, induction of pro-apoptotic and
inhibition of anti-apoptotic proteins
‚ Modulation signaling pathways (reduced
expression of plasma membrane receptors
overexpressed in cancer, decreased
phosphorylation of intracellular proteins) with
implications in tumor growth, invasion
and metastasis
‚ Generation of new classes of aromatase
inhibitors based on the structure of polyphenols
(flavones, isoflavones)
‚ Reduction in breast cancer risk in Chinese,
Japanese women; reduction in breast cancer risk
associated with high soy intake
during adolescence
‚ Decreased risk of breast cancer recurrence
(after daidzein intake)
‚ So far not successful in preventing cancer in
clinical trials
‚ Reduced bioavailability and stability
‚ Typically large concentrations have been used in
most in vitro studies which are unlikely to be
achieved in vivo
‚ The chemopreventive and therapeutic activity of
polyphenols as single agents or in combination
are studied in ongoing trials without
final conclusions
‚ Heterogeneity in the applied doses, duration of
administration, cells and animal models used in
the studies
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